Drug(concentration)	Skin prick test(dilution factor)	Intradermal test(dilution factor)

Midazolam (5 mg/ml)	5 mg/ml (pure)	0.5 mg/ml (1:10)

Propofol (10 mg/ml)	10 mg/ml (pure)	1 mg/ml (1:10)

Ketamine (10 mg/ml)	10 mg/ml (pure)	1 mg/ml (1:10)

Thiopental (25 mg/ml)	25 mg/ml (pure)	2.5 mg/ml (1:10)

Etomidate (2 mg/ml)	2 mg/ml (pure)	0.2 mg/ml (1:10)

Morphine (10 mg/ml)	1 mg/ml (1:10)	0.01 mg/ml (1:1000)

Fentanyl (0.05 mg/ml)	0.05 mg/ml (pure)	0.005 mg/ml (1:10)

Remifentanil (0.05 mg/ml)	0.05 mg/ml (pure)	0.005 mg/ml (1:10)

Sufentanil (0.005 mg/ml)	0.005 mg/ml (pure)	0.0005 mg/ml (1:10)

Alfentanil (0.5 mg/ml)	0.5 mg/ml (pure)	0.05 mg/ml (1:10)

Atracurium (10 mg/ml)	1 mg/ml (1:10)	0.01 mg/ml (1:1000)

Cisatracurium (2 mg/ml)	2 mg/ml (pure)	0.02 mg/ml (1:100)

Rocuronium (10 mg/ml)	10 mg/ml (pure)	0.05 mg/ml (1:200)

Mivacurium (2 mg/ml)	0.2 mg/ml (1:10)	0.002 mg/ml (1:1000)

Pancuronium (2 mg/ml)	2 mg/ml (pure)	0.2 mg/ml (1:10)

Vecuronium (4 mg/ml)	4 mg/ml (pure)	0.4 mg/ml (1:10)

Suxamethonium (50 mg/ml)	10 mg/ml (1:5)	0.1 mg/ml (1:500)

Drug(concentration)	Skin prick test(dilution factor)

Midazolam (5 mg/ml)	5 mg/ml (pure)

Propofol (10 mg/ml)	10 mg/ml (pure)

Ketamine (10 mg/ml)	10 mg/ml (pure)

Thiopental (25 mg/ml)	25 mg/ml (pure)

Etomidate (2 mg/ml)	2 mg/ml (pure)

Morphine (10 mg/ml)	1 mg/ml (1:10)

Fentanyl (0.05 mg/ml)	0.05 mg/ml (pure)

Remifentanil (0.05 mg/ml)	0.05 mg/ml (pure)

Sufentanil (0.005 mg/ml)	0.005 mg/ml (pure)

Alfentanil (0.5 mg/ml)	0.5 mg/ml (pure)

Atracurium (10 mg/ml)	1 mg/ml (1:10)

Cisatracurium (2 mg/ml)	2 mg/ml (pure)

Rocuronium (10 mg/ml)	10 mg/ml (pure)

Mivacurium (2 mg/ml)	0.2 mg/ml (1:10)

Pancuronium (2 mg/ml)	2 mg/ml (pure)

Vecuronium (4 mg/ml)	4 mg/ml (pure)

Suxamethonium (50 mg/ml)	10 mg/ml (1:5)


Child	Deficiency of the limb	Associated anomaly	Relation of the relative	Limb anomaly of the relative

1	split hand of right upper limb	none	sibling	(not reported)

2	split hand of right upper limb	none	sibling	(not reported)

3	split hand of right upper limb	none	sibling	(not reported)

4	split hand of right upper limb	none	sibling	(not reported)

5	split hand of both upper limbs and split foot of both lower limbs	none	sibling	(not reported)

6	radial deficiency of left upper limb	Fanconi’s anemia	sibling	(not reported)

7	ulnar deficiency of right upper limb	none	sibling	(not reported)

8	transverse deficiency at the level of hand of right upper limb	none	sibling	(not reported)

9	split hand of right upper limb	none	mother	anomalies of radius and ulna

10	split hand of right upper limb	none	father	split hand

11	split hand of both upper limbs	none	father	split hand

12	split hand of left upper limb and tibial deficiency of both lower limbs	none	granduncle	split hand

13	split foot of right lower limb	none	someone other than sibling	(not reported)

14	ulnar deficiency of both upper limbs and split foot of both lower limbs	Leri-Weill syndrome	mother	Madelung deformity, and Leri-Weill syndrome

15	ulnar deficiency of both upper limbs and tibial deficiency of both lower limbs	none	mother and grandmother	upper limb anomaly

16	transverse deficiency at the level of hand of right upper limb	none	relative on the mother’s side	toe defect

17	transverse deficiency at the level of foot of both lower limbs	none	father and grandfather on the father’s side	anomaly of fifth finger


Genus (family)	Order/suborder	Organelle genome	Inheritance	Reference

Equisetum (Equisetaceae)	Equisetales	Plastome	Maternal	Guillon and Raquin, 2000

Ceratopteris (Pteridaceae)	Polypodiales/Pteridineae	Plastome	Maternal	Adjie et al., 2007

Pellaea (Pteridaceae)	Polypodiales/Pteridineae	Plastome and mitogenome	Maternal	Gastony and Yatskievych, 1992

Asplenium (Aspleniaceae)	Polypodiales/Aspleniineae	Plastome	Maternal	Vogel et al., 1997

Deparia (Athyriaceae)	Polypodiales/Aspleniineae	Plastome and mitogenome	Maternal	This study


Date	Event

28 to 31 Oct 2008	Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)

9 to 10 Jul 2009	Sixth Session of the IGBC (Paris)

23 to 25 Nov 2009	Sixteenth Session of the IBC (Mexico City)

26 to 29 Oct 2010	Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris)

31 May to 2 Jun 2011	Eighteenth Session of the IBC* (Baku)

5 to 6 Sep 2011	Seventh Session of the IGBC* (Paris)

Date	Event

28 to 31 Oct 2008	Fifteenth Session of the IBC (2 days); Joint Session of the IBC and IGBC (2 days) (Paris)

9 to 10 Jul 2009	Sixth Session of the IGBC (Paris)

23 t	Sixteenth Session of the IBC

o 25 Nov 2009	(Mexico City)

26 to 29 Oct 2010	Seventeenth Session of the IBC (2 days)*,; Joint Session of the IBC and IGBC (2 days)* (Paris)

31 May to 2 Jun 2011	Eighteenth Session of the IBC* (Baku)

5 to 6 Sep 2011	Seventh Session of the IGBC* (Paris)


Whole group, n = 92

Age (median) 59.5 years

Gender:	Male	32 (35 %)

	Female	60 (65 %)

Treatment intent:	Palliative	7	Radical	85

N-stage	T-stage	No. of patients	% of total

 N0	T1	19	20.7

 N0	T2	37	40.2

 N0	T3	20	21.7

 N0	T4	6	6.5

 N1	T3	1	1.1

 N1	T4	4	4.4

 N2	T3	3	3.3

 N3	T3	1	1.1

 N3	T4	1	1.1

Radical treatment

Chemoradiotherapy plus boost, n = 52

Anal canal		Anal margin

Iridium boost, n = 36		Electron boost, n = 16

Age (median) 61 years		Age (median) 63 years

Stage	No. of patients (%)	Stage	No. of patients (%)

 T1 N0	3 (8.3)	T1 N0	4 (25)

 T2 N0	17 (47.2)	T2 N0	7 (43.8)

 T3 N0	14 (38.9)	T3 N0	2 (12.5)

 T2 N2	1 (2.8)	 –	–

 T3 N2	1 (2.8)	 –	–

–	–	T4 N0	2 (12.5)

–	–	T4 N1	1 (6.2)

Radical treatment (other)

External beam radiotherapy alone	8

Chemoradiotherapy without boost	25

Whole group, n = 92

Age (median) 59.5 years

Gender:	Male	32 (35 %)

	Female	60 (65 %)

Treatment intent:	Palliative	7	Radical	85

N-stag	T	No. of patients	% of total

Whole group, n = 92

Age (median) 59.5 years

Gender:	Male	32 (35 %)

	Female	60 (65 %)

Treatment intent:	Palliative	7	Radical	85

e	-stage

N0	T1	19	20.7

N0	T2	37	40.2

N0	T3	20	21.7

N0	T4	6	6.5

N1	T3	1	1.1

N1	T4	4	4.4

N2	T3	3	3.3

N3	T3	1	1.1

N3	T4	1	1.1

Radical treatment

Chemoradiotherapy plus boost, n = 52

Anal canal		Anal margin

Iridium boost, n = 36		Electron boost, n = 16

Age (median) 61 years		Age (median) 63 years

Stage	No. of patients (%)	Stage	No. of patients (%)

T1 N0	3 (8.3)	T1 N0	4 (25)

T2 N0	17 (47.2)	T2 N0	7 (43.8)

T3 N0	14 (38.9)	T3 N0	2 (12.5)

T2 N2	1 (2.8)	–	–

T3 N2	1 (2.8)	–	–

–	–	T4 N0	2 (12.5)

–	–	T4 N1	1 (6.2)

Radical treatment (other)

External beam radiotherapy alone	8

Chemoradiotherapy without boost	25


	Cell line	EC50 of MTX

MCF-7	human breast adenocarcinoma	2.58 × 10−8M

MDA-MB 231	human breast adenocarcinoma	5.06 × 10−7M

T-24	human bladder carcinoma	8.07 × 10−8M

PANC-1	human pancreatic carcinoma	2.34 × 10−8M

HT29	human colon adenocarcinoma	6.09 × 10−8M

A375	human melanoma	3.37 × 10−8M

HT-1376	human bladder carcinoma	1.71 × 10−7M

OVCAR-3	human ovarian carcinoma	8.95 × 10−8M

	Cell line	EC50 of MTX

T-24	human bladder carcinoma	8.07 × 10−8M

PANC-1	human pancreatic carcinoma	2.34 × 10−8M

HT29	human colon adenocarcinoma	6.09 × 10−8M

A375	human melanoma	3.37 × 10−8M

HT-1376	human bladder carcinoma	1.71 × 10−7M

OVCAR-3	human ovarian carcinoma	8.95 × 10−8M


Estimators	WF population	BF population

BREAST CANCER	Scenario 1	Scenario 2	Scenario 3	Scenario 1	Scenario 2	Scenario 3

Observed rates	0.973	0.974	0.975	0.956	0.964	0.965

Population-weighted average	0.967	0.943	0.968	0.887	0.761	0.910

Global Empirical Bayes	0.847	0.843	0.974	0.908	0.787	0.804


Strain name	Genotype	Reference

yMD7	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg	This study

	pep4::KanMX

	MCM6::MCM6-3 × FLAG (Nat-NT2)

yMD8	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100 bar1::Hyg	This study

	pep4::KanMX

	MCM6::MCM6-3 × FLAG (Nat-NT2)

	his3::HIS3pRS303/CDT1,GAL4

	trp1::TRP1pRS304/MCM4, MCM5 leu2::LEU2pRS305/MCM6TC, MCM7 ura3::URA3pRS306/MCM2, CBP-MCM3

yMD9	MATaade2-1 ura3-1 his3-11,15 trp1-1 leu2-3,112 can1-100,	This study

	cdc7-4, pep4:: Hyg,

	MCM10::MCM10-3 × FLAG (Nat-NT2)

	his3::HIS3pRS303/SLD3-13MYC,

	trp1::TRP1pRS304/SLD2, leu2::LEU2pRS305/SLD7, CDC45,

	ura3::URA3pRS306/DPB11

yMD16	MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2)	This study

yMD17	MATa/α ade2-1/ade2-1 ura3-1/ura3-1 his3-11,15/his3-11,15 trp1-1/trp1-1 leu2-3,112/leu2-3,112 can1-100/can1-100 MCM10+/mcm10Δ472-571 (Nat-NT2) RAD9/rad9Δ::KanMX	This study


	KEGG ID	KEGG term	HypergeometricP-value	CorrectedP-value (BF)

	hsa05200	Pathways in cancer	6.16E−08	1.23E−05

	hsa04110	Cell cycle	7.96E−08	1.58E−05

	hsa04144	Endocytosis	1.34E−07	2.67E−05

Down	hsa04520	Adherens junction	2.55E−07	5.08E−05

	hsa04310	Wnt signaling pathway	1.16E−06	2.31E−04

	hsa05220	Chronic myeloid leukemia	4.39E−06	8.73E−04

	hsa04114	Oocyte meiosis	4.90E−06	9.75E−04

	hsa05200	Pathways in cancer	2.47E−09	5.14E−07

	hsa05220	Chronic myeloid leukemia	4.54E−08	9.45E−06

	hsa04144	Endocytosis	3.80E−07	7.91E−05

	hsa05215	Prostate cancer	7.45E−07	1.55E−04

Up	hsa04110	Cell cycle	7.71E−07	1.60E−04

	hsa04115	p53 signaling pathway	2.31E−06	4.80E−04

	hsa04120	Ubiquitin mediated proteolysis	2.33E−06	4.84E−04

	hsa05210	Colorectal cancer	2.51E−06	5.22E−04

	hsa04520	Adherens junction	2.82E−06	5.87E−04

	KEGG ID	KEGG term	HypergeometricP-value	CorrectedP-value (BF)

Down	hsa04520	Adherens junction	2.55E−07	5.08E−05

	hsa04310	Wnt signaling pathway	1.16E−06	2.31E−04

	hsa05220	Chronic myeloid leukemia	4.39E−06	8.73E−04

	hsa04114	Oocyte meiosis	4.90E−06	9.75E−04

	hsa05200	Pathways in cancer	2.47E−09	5.14E−07

	hsa05220	Chronic myeloid leukemia	4.54E−08	9.45E−06

	hsa04144	Endocytosis	3.80E−07	7.91E−05

	hsa05215	Prostate cancer	7.45E−07	1.55E−04

Up	hsa04110	Cell cycle	7.71E−07	1.60E−04

	hsa04115	p53 signaling pathway	2.31E−06	4.80E−04

	hsa04120	Ubiquitin mediated proteolysis	2.33E−06	4.84E−04

	hsa05210	Colorectal cancer	2.51E−06	5.22E−04

	hsa04520	Adherens junction	2.82E−06	5.87E−04


plasma DBP (μg/mL)	GAgP group (n = 59)	Control group (n = 58)

r 	P value	r 	P value

Mean BI	0.1588	0.251	0.048	0.768

Mean PD	−0.1347	0.327	−0.190	0.216

Mean AL	−0.164	0.230	None	—

Severe sites %	−0.167	0.233	None	—

plasma DBP (μg/mL)	GAgP group (n = 59)	Control group (n = 58)

r	P value	r	P value

Mean AL	−0.164	0.230	None	—

Severe sites %	−0.167	0.233	None	—


NCC material	After 48 h	After 336 h	After 336 h + freezing and thawing

Untreated	−	−	+

10 kGy	+	+	+

20 kGy	+/− 1	+	+

30 kGy	−	+/− 1	+

40 kGy	−	+/− 1	+

50 kGy	−	−	+

60 kGy	−	−	−


Group	Mean calluses width, mm ± SD	Mean calluses length, mm ± SD	Regeneration zones ± SD	Embryogenesis appearance, %

Control	4.18 ± 1.36	6.22 ± 0.67	1.24 ± 0.48	20

AgNPs	5.37 ± 3.47	7.00 ± 2.54	2.01 ± 0.98	34

AuNPs	6.39 ± 2.82	6.55 ± 2.36	3.29 ± 1.07	49

Mean calluses width, mm ± SD	Mean calluses length, mm ± SD	Regeneration zones ± SD	Embryogenesis appearance, %

4.18 ± 1.36	6.22 ± 0.67	1.24 ± 0.48	20

5.37 ± 3.47	7.00 ± 2.54	2.01 ± 0.98	34

6.39 ± 2.82	6.55 ± 2.36	3.29 ± 1.07	49


Surgery	Ratio between post-discharge SSIs and in-hospital SSIs

Vascular surgery	0

Breast surgery	3,4

Cesarean section	2,5

Cholecistectomy	1,2

Gastric surgery	0,4

Appendectomy	0,2

Colon surgery	0,1

Hernia repair	1,4

Abdominal hysterectomy	0,6

Vaginal hysterectomy	1


Outcome Measures	Importance	Validity	Scientific soundness	Usability	Feasibility	Ranking

CGI-SCH	HIGH	HIGH	MED	MED	HIGH	1

Degree of involvement in vocational rehabilitation	HIGH	HIGH	MED	MED	HIGH

Brief Psychiatric Rating Scale	MED	HIGH	MED	MED	MED

Degree of Independent Living	HIGH	HIGH	MED	LOW	MED

PANSS	MED	MED	MED	MED	LOW

Service user Satisfaction Survey Responses	HIGH	LOW	LOW	MED	MED

Development of Metabolic Syndrome/Diabetes	HIGH	HIGH	MED	MED	MED

GAF Score	MED	MED	MED	MED	MED

Process Adherence Measures

 Percentage of Service users on Multiple Antipsychotics (excluding clozapine)	MED	HIGH	MED	HIGH	MED	1

 Percentage of service users who have metabolic monitoring at recommended intervals	HIGH	HIGH	HIGH	HIGH	LOW	2

 Percentage of service users referred for supported employment/vocational services	HIGH	MED	HIGH	HIGH	HIGH	3

 Percentage of service users referred to CBT for psychosis	HIGH	MED	HIGH	HIGH	HIGH	4

 Percentage of service users on recommended dosages (within therapeutic range) of antipsychotic medication	MED	MED	MED	HIGH	LOW

 Percentage of service users with a summary of previous medication trials	MED	MED	MED	HIGH	MED

 Percentage of first-episode service users who have had a MRI brain	MED	LOW	LOW	HIGH	HIGH

 Percentage of service users that have an annual physical exam	MED	LOW	LOW	HIGH	HIGH


Ingenuity Canonical Pathwaya	C2b	C3	C4

Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F	3.47E-08

Communication between Innate and Adaptive Immune Cells	6.17E-08

TREM1 Signaling	1.1E-07

Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F	2.09E-07

Role of Cytokines in Mediating Communication between Immune Cells	0.000331

MSP-RON Signaling Pathway	0.000331

Dendritic Cell Maturation	0.000427

Acute Phase Response Signaling	0.002399

Crosstalk between Dendritic Cells and Natural Killer Cells	0.002455

IL-17A Signaling in Fibroblasts	0.002754

Chemokine Signaling	0.012303

Glucocorticoid Receptor Signaling	0.016218

NF-kB Signaling	0.016982

LXR/RXR Activation	0.032359

p38 MAPK Signaling	0.033884

IL-6 Signaling	0.038019

IL-12 Signaling and Production in Macrophages	0.038905

G-Protein Coupled Receptor Signaling		0.006166

Role of PI3K/AKT Signaling in the Pathogenesis of Influenza		0.019055

Crosstalk between Dendritic Cells and Natural Killer Cells		0.039811

Activation of IRF by Cytosolic Pattern Recognition Receptors			1.58E-11

Interferon Signaling			1.23E-10

Role of RIG1-like Receptors in Antiviral Innate Immunity			2.24E-05

Retinoic acid Mediated Apoptosis Signaling			0.000148

Role of PKR in Interferon Induction and Antiviral Response			0.000832

Role of JAK1, JAK2 and TYK2 in Interferon Signaling			0.002884

Role of MAPK Signaling in the Pathogenesis of Influenza			0.032359

IL-10 Signaling	0.012303	0.00537

Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	3.31E-05		3.24E-08

Role of IL-17F in Allergic Inflammatory Airway Diseases	0.000257		0.010965

Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	0.000132	0.000891	0.006918

Ingenuity Canonical Pathwaya	C2b	C3	C4

Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F	3.47E-08

Communication between Innate and Adaptive Immune Cells	6.17E-08

TREM1 Signaling	1.1E-07

Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F	2.09E-07

Role of Cytokines in Mediating Communication between Immune Cells	0.000331

MSP-RON Signaling Pathway	0.000331

Dendritic Cell Maturation	0.000427

Acute Phase Response Signaling	0.002399

Crosstalk between Dendritic Cells and Natural Killer Cells	0.002455

IL-17A Signaling in Fibroblasts	0.002754

Chemokine Signaling	0.012303

Glucocorticoid Receptor Signaling	0.016218

NF-kB Signaling	0.016982

LXR/RXR Activation	0.032359

p38 MAPK Signaling	0.033884

IL-6 Signaling	0.038019

IL-12 Signaling and Production in 	0.038

Ingenuity Canonical Pathwaya	C2b	C3	C4

Macrophages	905

G-Protein Coupled Receptor Signaling		0.006166

Role of PI3K/AKT Signaling in the Pathogenesis of Influenza		0.019055

Crosstalk between Dendritic Cells and Natural Killer Cells		0.039811

Activation of IRF by Cytosolic Pattern Recognition Receptors			1.58E-11

Interferon Signaling			1.23E-10

Role of RIG1-like Receptors in Antiviral Innate Immunity			2.24E-05

Retinoic acid Mediated Apoptosis Signaling			0.000148

Role of PKR in Interferon Induction and Antiviral Response			0.000832

Role of JAK1, JAK2 and TYK2 in Interferon Signaling			0.002884

Role of MAPK Signaling in the Pathogenesis of Influenza			0.032359

IL-10 Signaling	0.012303	0.00537

Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses	3.31E-05		3.24E-08

Role of IL-17F in Allergic Inflammatory Airway Diseases	0.000257		0.010965

Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza	0.000132	0.000891	0.006918


Characteristic	Burkina Faso*	Senegal*	Niger*	Ghana*

Surveillance design	Prospective	Retrospective	Retrospective	Prospective

Geographic extent	Three districts	Dakar	Niamey	Northern area

Surveillance population	880,000	950,000	550,000	140,000

Rural/Urban	Both	Urban	Urban	Rural

Study years	2002-2005	1970-1979	1981-1996	1998-2003

Microbiological methods	Culture, antigen detection, PCR	Culture	Culture, antigen detection	Culture, antigen detection

Number of confirmed pneumococcal meningitis cases	249	983	934	76

Percent of cases occurring during dry/epidemic season months of Dec-Apr†	75%	49%	63%	69%

Two months with peak number of cases (percent of total)†	Jan-Feb (38%)	Feb-Mar (21%)	Feb-Mar (31%)	Dec-Jan (35%)

Relation of pneumococcal to meningococcal seasonal peak	Similar	2 months in advance	1 month in advance	1 to 2 months in advance

13-valent conjugate vaccine coverage of isolated serotypes

Age <5 years	67%	78% (age<2 yrs)	No serotype data	100%

Age 5+ years	77%	94% (age 2+ yrs)	No serotype data	98%

Reference	4,5	9	8	7

Characteristic

Surveillance design

Geographic extent

Surveillance population

Rural/Urban

Study years

Microbiological methods

Number of confirmed pneumococcal meningitis cases

Percent of cases occurring during dry/epidemic season months of Dec-Apr†

Two months with peak number of cases (percent of total)†

Relation of pneumococcal to meningococcal seasonal peak

13-valent conjugate vaccine coverage of isolated serotypes

Age <5 years

Age 5+ years

Reference

Burkina Faso*	Senegal*	Niger*	Ghana*

Prospective	Retrospective	Retrospective	Prospective

Three districts	Dakar	Niamey	Northern area

880,000	950,000	550,000	140,000

Both	Urban	Urban	Rural

2002-2005	1970-1979	1981-1996	1998-2003

Culture, antigen detection, PCR	Culture	Culture, antigen detection	Culture, antigen detection

249	983	934	76

75%	49%	63%	69%

Jan-Feb (38%)	Feb-Mar (21%)	Feb-Mar (31%)	Dec-Jan (35%)

Similar	2 months in advance	1 month in advance	1 to 2 months in advance

67%	78% (age<2 yrs)	No serotype data	100%

77%	94% (age 2+ yrs)	No serotype data	98%

4,5	9	8	7


Algal species	Protein	Carbohydrates	Lipids

Anabaena cylindrica[96]	43–56	25–30	4–7

Aphanizomenon flos-aquae[96]	62	23	3

Chlamydomonas reinhardtii[96]	48	17	21

Chlorella minutissima[21]	9–24	14–42	31–57

Auxenochlorella protothecoides[97]	11–26	17–24	25–54

Auxenochlorella protothecoides[21]	36–38	41–52	11–23

Chlorella pyrenoidosa[96]	57	26	2

Chlorella emersonii[21]	28–32	11–41	29–63

Chlorella sorokiniana[21]	42–45	32–38	20–22

Chlorella vulgaris[96]	51–58	12–17	14–22

Chlorella vulgaris[21]	7–29	51–55	18–40

Dunaliella salina[96]	57	32	6

Euglena gracilis[96]	39–61	14–18	14–20

Nannochloropsis sp.[98]	23–59	5–17	9–62

Porphyridium cruentum[96]	28–39	40–57	9–14

Scenedesmus obliquus[96]	50–56	10–17	12–14

Spirogyra sp.[96]	6–20	33–64	11–21

Arthrospira maxima[96]	60–71	13–16	6–7

Spirulina platensis[96]	46–63	8–14	4–9

Synechococcus sp.[96]	63	15	11

Algal species

Anabaena cylindrica[96]

Aphanizomenon flos-aquae[96]

Chlamydomonas reinhardtii[96]

Chlorella minutissima[21]

Auxenochlorella protothecoides[97]

Auxenochlorella protothecoides[21]

Chlorella pyrenoidosa[96]

Chlorella emersonii[21]

Chlorella sorokiniana[21]

Chlorella vulgaris[96]

Chlorella vulgaris[21]

Dunaliella salina[96]

Euglena gracilis[96]

Nannochloropsis sp.[98]

Porphyridium cruentum[96]

Scenedesmus obliquus[96]

Spirogyra sp.[96]

Arthrospira maxima[96]

Spirulina platensis[96]

Synechococcus sp.[96]


Factors	Post-progression survival

Hazard ratio	95% CI	p-value

Age (years) at the beginning of first-line treatment	0.98	0.94–1.02	0.47

Chemoradiotherapy (sequential/concurrent)	2.25	0.66–7.04	0.18

Best response at second-line treatment (NonPD/PD)	0.22	0.10–0.47	< 0.01

Distant metastases at recurrence (yes/no)	2.42	1.18–5.22	0.01

Administration of platinum-based agents after first-line treatment (yes/no)	0.92	0.41–1.98	0.83

Number of regimens after first-line treatment	0.75	0.56–0.98	0.04

Factors

Age (years) at the beginning of first-line treatment	0.98	0.94–1.02	0.47

Chemoradiotherapy (sequential/concurrent)	2.25	0.66–7.04	0.18

Best response at second-line treatment (NonPD/PD)	0.22	0.10–0.47	< 0.01

Distant metastases at recurrence (yes/no)	2.42	1.18–5.22	0.01

Administration of platinum-based agents after first-line treatment (yes/no)	0.92	0.41–1.98	0.83

Number of regimens after first-line treatment	0.75	0.56–0.98	0.04


Route	N	(%)

Internet	2511	(42.0)

TV or Movie	3185	(53.2)

Retail Store	2138	(35.7)

Billboard	810	(13.6)

Vehicle	483	(8.1)

Event	686	(11.5)

Magazine or newspaper	2062	(34.9)

Route

Internet

TV or Movie

Retail Store

Billboard

Vehicle

Event

Magazine or newspaper


SLE patients

Gender (female: male)

Age (year)

Leukocytes (×1000/ml)

Hemoglobulin (mg/dL)

Neutrophil (%)

Lymphocyte (%)

Platelets (1000/μL)

Alanine aminotransferase (U/dL)

Erythrocyte Sediment Rate (mm/hr)

Albumin (mg/dL)

anti-dsDNA (U/dL)

C3 (mg/dL)

C4 (mg/dL)

Creatinine (mg/dL)

Urine protein/Creatinine


Cohort 3	Patients with ∆ reticulin and/or collagena (N = 7)	Patients with no ∆ collagen or reticulin (N = 51)

Age, median (Q1, Q3), years	47 (30, 60)	44 (33, 61)

ITP duration, median (Q1, Q3), years	4.1 (1.2, 9.1)	2.2 (1.2, 7.1)

Prior splenectomy rate, n (%)	2 (29)	17 (33)

Platelet responseb, median (Q1, Q3)	Time to first platelet response, weeks	15 (7, 21)c	3 (2, 8)d

Weeks with platelet response, %	5 (0, 28)	38 (28, 76)

Exposuree, median (Q1, Q3)	Average weekly dose, μg/kg	9 (7, 9)	2 (1, 5)

Maximum weekly dose, μg/kg	10 (9, 10)	4 (3, 10)

Cumulative dose, μg/kg	1207 (204, 1358)	345 (136, 610)


Pollen recipient (♀)	Pollen donor (♂)	Number of flowers	Number of fruits	Fruit set (%)	Mean number of seeds per fruit	Seed viability (%)	Mean number of viable seeds per fruita

B. crispa	B. crispa	20	11	55	65.50	34	22.27

	B. officinalis	24	14	58	8.00	68	5.44

	Putative hybrid	27	15	55	2.20	70	1.54

B. officinalis	B. crispa	32	2	6	1.00	0	0.00

	B. officinalis	23	10	43	65.00	91	59.15

	Putative hybrid	37	18	48	1.94	57	1.11

Putative hybrid	B. crispa	31	19	61	2.79	0	0.00

	B. officinalis	38	32	84	4.63	53	2.45

	Putative hybrid	45	7	15	0.43	0	0.00


	control	LBBB

valvular, n (%)	-	1 (3.0%)


	Stroke/TIA Patients	Control Subjects	Significance

Age, yr	53.9±9.3	53.8±9.0	ns.

Males, n (%)	21 (52.5)	21 (52.5)	ns.

Body mass index, kg/m2	28.7±4.8	25.3±4.1	0.002

Body surface area, m2	2.0±0.2	1.8±0.2	0.033

Caucasian race, n (%)	40 (100.0)	40 (100.0)	ns.

Hypertension, n (%)	16 (40.0)	0 (0.0)	<0.001

Hyperlipidemia, n (%)	14 (35.0)	16 (40.0)	ns.

Diabetes, n (%)	0 (0.0)	0 (0.0)	ns.

Left ventricle ejection fraction, %	66.0±10.2	63.7±7.7	ns.

Left ventricle dysfunction, n (%)	0 (0.0)	0 (0.0)	ns.

Smokers, n (%)	0 (0.0)	1 (2.5)	ns.

	Stroke/TIA Patients	Control Subjects	Significance

Hypertension, n (%)	16 (40.0)	0 (0.0)	<0.001

Hyperlipidemia, n (%)	14 (35.0)	16 (40.0)	ns.

Diabetes, n (%)	0 (0.0)	0 (0.0)	ns.

Left ventricle ejection fraction, %	66.0±10.2	63.7±7.7	ns.

Left ventricle dysfunction, n (%)	0 (0.0)	0 (0.0)	ns.

Smokers, n (%)	0 (0.0)	1 (2.5)	ns.


Characteristics	n = 10

Age	63.8±12.0

Body Mass Index	27.1±3.7

Parity	2 (1-3)

Health problems	6

SUI	2

Previous hysterectomy	5

Previous POP surgery	10

POP	10

Point C/D POPQ median (range)	3 (2-4)

Central compartment prolapse stage ≥ 3	10

Cystocele stage ≥ 2	9

Rectocele stage ≥ 2	7

Enterocele stage ≥ 2	0

Concomitant procedure	6

Anterior colporrhaphy	4

Posterior colporrhaphy	2

MUS	0


 	Infection-associated EHPM (+)	Infection-associated EHPM (−)	Odds ratio (95% CI)	P value

HCV Ab (+)	27	240	3.15 (1.19–8.37)	0.0194

HCV Ab (−)	5	140

HBs Ag (+)	4	61	11.31 (2.03–63.11)	0.0067

HBs Ag (−)	2	345

No viral infection	4	67	20.30 (2.23–184.46)	0.0036

Any viral infection 	1	340


miRNAs	Known functional effect	Targets	References

mir-15a, miR-15b, miR-16, and miR-195	Pancreas development, beta-cells fate and regeneration	Neurog3	[33]

miR-375	Beta- and alpha-cells expansion	 	[42]

miR-7a	Beta-cell proliferation	mTOR pathway components	[44, 45, 48]

miR-124a	Pancreas development	Foxa2	[33]

miRNAs	Known functional effect	Targets	References

miR-375	Beta- and alpha-cells expansion		[42]

miR-7a	Beta-cell proliferation	mTOR pathway components	[44, 45, 48]

miR-124a	Pancreas development	Foxa2	[33]


Patient/source	Our patient	Patients TB/LB from Joyce et al. [13]	Patient DP from Monk et al. [17]	Patients HC/AC from Monk et al. [16]	Patient from Eggermann et al. [6] (decipher 285981)	Decipher 289205	Decipher 276327	ISCA nssv579045

Genomic location (hg19)	chr7:50654827-5122921	chr7:42029531–51138357(D7S691-D7S242)	chr7:40742989–50861159 (D7S1769-GRB10)	chr7:41392336–54000000 (RP5-953B5-7p11.2)	chr7:47034222–52175639	chr7:50713413-50982532	chr7:43566637-51282735	chr7:33367924-61831899

Duplication size	574Kb	~10 cM	~10 cM	>10 cM	5.1 Mb	270Kb	7.72 Mb	28.5 Mb

Inheritance/orign	de novo/maternal	LB: maternal	de novo/maternal	AC: maternal	de novo/paternal	inherited/paternal	de novo/unknown	unknown

TB: paternal	HC: unknown

Phenotype	SRS	SRS	SRS	SRS-like	overgrowth, DD, microcephaly, seizure	hypotonia, GDD	muscular hypotonia	FTT, GDD, large eyes, microcephaly, short stature, triangular face

Detection method	array	karyotype/FISH	karyotype/FISH	karyotype/FISH	array	array	array	array

Genes involved (Refseq)	GRB10 and part of COBL	>50 genes	>50 genes	>50 genes	>20 genes	Part of GRB10	>40 genes	>180 genes


Group	Treatment (mg/kg) once daily orally		Study 1	Study 2

A	None (placebo, control)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

B	Benazepril (0.5–1.0)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

C	Robenacoxib (1.0–2.4)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f

D	Benazepril (0.5–1.0) + Robenacoxib (1.0–2.4)	Cohort 1	4 f	2 m & 2 f

Cohort 2	4 m	2 m & 2 f


	%T0	%24-hour	Fold change	P value

a.) The most abundant members at time zero

Oxalobacteraceae	38.63	0.96	−40.21	0.0002

Pseudomonadaceae	10.62	1.36	−7.79	0.0158

Flavobacteriaceae	7.33	0.22	−33.12	0.0002

Comamonadaceae	5.03	2.43	−2.07	0.1982

Xanthomonadaceae	4.11	0.87	−4.72	0.0154

Rhizobiaceae	3.57	0.13	−27.76	0.0002

Methylobacteriaceae	3.50	0.03	−140.14	0.0002

Micrococcaceae	2.52	0.01	−176.45	0.0002

Sphingomonadaceae	2.28	0.03	−79.78	0.0002

Weeksellaceae	2.20	0.07	−33.30	0.0002

Rhodobacteraceae	2.11	0.03	−73.74	0.0002

Microbacteriaceae	2.06	0.02	−104.63	0.0002

[Exiguobacteraceae]	1.84	6.20	3.37	0.0002

Caulobacteraceae	1.58	0.03	−55.16	0.0002

Rickettsiales	1.32	0.01	−92.45	0.0002

Sphingobacteriaceae	1.29	0.08	−17.20	0.0002

Enterobacteriaceae	1.14	3.59	3.13	0.0288

Aurantimonadaceae	1.01	0.01	−93.98	0.0002

Paenibacillaceae	0.99	1.51	1.52	0.1238

Rhizobiales;Other	0.62	0.04	−14.56	0.0002

Bacillaceae	0.61	3.08	5.01	0.0002

Cytophagaceae	0.60	0.01	−111.36	0.0002

b.) The most abundant members after a 24-hour mBPW enrichment

Peptostreptococcaceae	0.01	40.79	2957.09	0.0002

Planococcaceae	0.31	19.49	62.11	0.0002

Clostridiaceae	0.03	13.54	490.93	0.0002

[Exiguobacteraceae]	1.84	6.20	3.37	0.0002

Enterobacteriaceae	1.14	3.59	3.13	0.0288

Bacillaceae	0.61	3.08	5.01	0.0002


Extract of questionnaire

Frequency of muscle pain that was reported in clinical trials on statins:

	Statins	Placebo	p-value

 Cochrane 2013 N = 37,938, primary prevention	9.5 %	9.2 %	0.40

 Finegold 2014 N = 46,262, primary prevention	7.9 %	7.6 %	0.407

 Finegold 2014 N = 37,618, secondary prevention	4.8 %	4.6 %	0.558

Question: If 100 patients take this statin – in how many of them does the intake of this statin cause muscle pain?a

 Responses (No)	0	1	>1	>10	No response

 Format multiple choice

 Group 6 (n = 87) Pharmacy group	10 (12 %)	12 (14 %)	48 (55 %)	14 (16 %)	3 (3 %)

Format multiple choice	0	1	>1	>10	No response

Group 6 (n = 87) Pharmacy group	10 (12 %)	12 (14 %)	48 (55 %)	14 (16 %)	3 (3 %)


Themes	Subthemes	Representative statements

Cultural and linguistic barriers 	Major barriers in terms of language and culture result in older adults' dependency on others when it comes to medical visits	“The biggest problem is the language barrier. We feel helpless since we do not speak English, and we cannot resolve matters without English. Even if you understand English you would not comprehend their technical terms.” “The people I contact are few. I don't want to bother my children.”

Immediate family support may not always be available to assist older adults with medical visits	“If you need your son to bring you to the doctor's clinic, he would have no time because he has to work. If you cannot find someone else, then you just have to wait until he comes home.” “To ride the bus you need to know how to get there... you need to draw it on a piece of paper with the directions. I was to take bus no. 4, and it would transfer three times. But still I did not make it (to the hospital). I was lucky to return home from the final bus stop.”

Affordability of services 	The health care system is poorly understood. The utilization and degree of satisfaction differ depending on older adults' insurance coverage and length of residence	“As new comers, we have nothing. My mother-in-law is old, and, moreover, I am old too, I am sixty eight years old. As we age, the most critical thing is medical treatment and benefits. Getting your white card, it would not be a big deal even if you are sick. We depend on the medical supply by mail. It is tough to see a doctor. Besides it is far away. And not knowing English, it is difficult to visit a doctor. The medical expenses are high.” “It's like we have to pay for everything. We have nothing and yet we need to pay for the medication expenses.”

For those who are fully insured, they feel fortunate compared to that of their counterparts in China	“Buying insurance is now only getting started in China. Previously, I bought insurance. Now I apply for low-income status. So I do not have to buy insurance and it is so much better. America is definitely taking that route. You have no money. The government helps out with a low income status. If you apply, it will not cost you any money.” “I think the most pleasant thing for me in the US is what happened to my two legs. My legs were broken twice in the US if that happened in China, my children and I would not be able to afford the surgeries. Here in the US, I do not have to pay a single cent. They even provided me the walking equipment and the toilet pans. I think this is the best thing happened to me. I feel very happy and thankful for that.”

Availability of services 	The long wait and inflexibility of health care services often frustrated participants	“I think the waiting period to see a doctor is too long. It takes several hours and you are not seeing your doctor right away. Definitely it is too long.” “I think there is something that America is not comparable to China. That is the appointment system. They are not letting you see the doctor today, unless you are going to the emergency room! They will not let you see the doctor right away; it would take a week. Then you need to go to the emergency room. I think that situation is not good.”

The expectation toward medical visits is often compared to older participants' experience in China where quick improvement is anticipated	“In Shanghai, if I do not feel good, I can go to see the doctor right away. Over here, this appointment thing, you would need two weeks to see your family physician. He has his vacations and you need to wait two weeks. But hey, I am sick... I have this illness and I need to see the doc right away. I think over here, you need to go to the hospital, the UIC Hospital. It is because of the insurance that requires you to visit the hospital. Today you can visit this hospital and tomorrow you can visit that hospital. And that is OK.” “Like suffering from nerve pain... if you are in China, you just visit the clinic to get a pain killer shot. Over here the waiting period is not fast. I went there and took several hours. Going to the hospital for minor ailments is not convenient.”.

Themes	Subthemes

Cultural and linguistic barriers	Major barriers in terms of language and culture result in older adults' dependency on others when it comes to medical visits

Immediate family support may not always be available to assist older adults with medical visits

Affordability of services	The health care system is poorly understood. The utilization and degree of satisfaction differ depending on older adults' insurance coverage and length of residence

For those who are fully insured, they feel fortunate compared to that of their counterparts in China

Availability of services	The long wait and inflexibility of health care services often frustrated participants

The expectation toward medical visits is often compared to older participants' experience in China where quick improvement is anticipated

Representative statements

“The biggest problem is the language barrier. We feel helpless since we do not speak English, and we cannot resolve matters without English. Even if you understand English you would not comprehend their technical terms.” “The people I contact are few. I don't want to bother my children.”

“If you need your son to bring you to the doctor's clinic, he would have no time because he has to work. If you cannot find someone else, then you just have to wait until he comes home.” “To ride the bus you need to know how to get there... you need to draw it on a piece of paper with the directions. I was to take bus no. 4, and it would transfer three times. But still I did not make it (to the hospital). I was lucky to return home from the final bus stop.”

“As new comers, we have nothing. My mother-in-law is old, and, moreover, I am old too, I am sixty eight years old. As we age, the most critical thing is medical treatment and benefits. Getting your white card, it would not be a big deal even if you are sick. We depend on the medical supply by mail. It is tough to see a doctor. Besides it is far away. And not knowing English, it is difficult to visit a doctor. The medical expenses are high.” “It's like we have to pay for everything. We have nothing and yet we need to pay for the medication expenses.”

“Buying insurance is now only getting started in China. Previously, I bought insurance. Now I apply for low-income status. So I do not have to buy insurance and it is so much better. America is definitely taking that route. You have no money. The government helps out with a low income status. If you apply, it will not cost you any money.” “I think the most pleasant thing for me in the US is what happened to my two legs. My legs were broken twice in the US if that happened in China, my children and I would not be able to afford the surgeries. Here in the US, I do not have to pay a single cent. They even provided me the walking equipment and the toilet pans. I think this is the best thing happened to me. I feel very happy and thankful for that.”

“I think the waiting period to see a doctor is too long. It takes several hours and you are not seeing your doctor right away. Definitely it is too long.” “I think there is something that America is not comparable to China. That is the appointment system. They are not letting you see the doctor today, unless you are going to the emergency room! They will not let you see the doctor right away; it would take a week. Then you need to go to the emergency room. I think that situation is not good.”

“In Shanghai, if I do not feel good, I can go to see the doctor right away. Over here, this appointment thing, you would need two weeks to see your family physician. He has his vacations and you need to wait two weeks. But hey, I am sick... I have this illness and I need to see the doc right away. I think over here, you need to go to the hospital, the UIC Hospital. It is because of the insurance that requires you to visit the hospital. Today you can visit this hospital and tomorrow you can visit that hospital. And that is OK.” “Like suffering from nerve pain... if you are in China, you just visit the clinic to get a pain killer shot. Over here the waiting period is not fast. I went there and took several hours. Going to the hospital for minor ailments is not convenient.”.


Performance parameter	Melody type

	Simple	Complex

8th note onset	0.57	0.49

16th note onset	0.38	0.54

Micro-timing onset	0.14	−0.12

8th note offset	0.48	0.09

16th note offset	0.23	0.26

Micro-timing offset	−0.09	−0.02

8th note duration	−0.37	−0.35

16th note duration	−0.17	−0.23

Micro-timing duration	−0.05	−0.08

Density	0.51	0.38

R2 (variance explained)	0.562	0.532

Performance parameter	Melody type

	Simple	Complex

16th note offset	0.23	0.26

Micro-timing offset	−0.09	−0.02

8th note duration	−0.37	−0.35

16th note duration	−0.17	−0.23

Micro-timing duration	−0.05	−0.08

Density	0.51	0.38

R2 (variance explained)	0.562	0.532


Construct name	Primer combination

NbPDS (2046 bp)	NbPDSfor1 × NbPDSrev1

NbPDS (1661 bp)	NbPDSfor2 × NbPDSrev1

NbPDS (1304 bp)	NbPDSfor3 × NbPDSrev1

NbPDS (959 bp)	NbPDSfor4 × NbPDSrev1

NbPDS (610 bp)	NbPDSfor5 × NbPDSrev1

NbPDS (257 bp)	NbPDSfor6 × NbPDSrev1

NbPDS (345 bp)	NbPDSfor3 × NbPDSrev2

NbPDS (192 bp)	NbPDSfor7 × NbPDSrev3

NbPDS (103 bp)	NbPDSfor7 × NbPDSrev4

NbPDS (54 bp)	NbPDSfor8 × NbPDSrev5

NbPDS (385 bp)	NbPDSfor1 × NbPDSrev6

NbPDS (357 bp)	NbPDSfor2 × NbPDSrev7

NbPDS (349 bp)	NbPDSfor4 × NbPDSrev8

NbPDS (353 bp)	NbPDSfor5 × NbPDSrev9

NbPDS (2046 bp + polyA)	NbPDSfor1 × NbPDSrev6

NbPDS (1661 bp + polyA)	NbPDSfor2 × NbPDSrev6

NbPDS (1304 bp + polyA)	NbPDSfor3 × NbPDSrev6

NbPDS (959 bp + polyA)	NbPDSfor4 × NbPDSrev6

NbPDS (610 bp + polyA)	NbPDSfor5 × NbPDSrev6

NbPDS (257 bp + polyA)	NbPDSfor6 × NbPDSrev6

NbPDS (345 bp + polyA)	NbPDSfor7 × NbPDSrev7

NbPDS (345 bp + polyG)	NbPDSfor7 × NbPDSrev8

Construct name	Primer combination

	 × NbPDSrev3

NbPDS (103 bp)	NbPDSfor7 × NbPDSrev4

NbPDS (54 bp)	NbPDSfor8 × NbPDSrev5

NbPDS (385 bp)	NbPDSfor1 × NbPDSrev6

NbPDS (357 bp)	NbPDSfor2 × NbPDSrev7

NbPDS (349 bp)	NbPDSfor4 × NbPDSrev8

NbPDS (353 bp)	NbPDSfor5 × NbPDSrev9

NbPDS (2046 bp + polyA)	NbPDSfor1 × NbPDSrev6

NbPDS (1661 bp + polyA)	NbPDSfor2 × NbPDSrev6

NbPDS (1304 bp + polyA)	NbPDSfor3 × NbPDSrev6

NbPDS (959 bp + polyA)	NbPDSfor4 × NbPDSrev6

NbPDS (610 bp + polyA)	NbPDSfor5 × NbPDSrev6

NbPDS (257 bp + polyA)	NbPDSfor6 × NbPDSrev6

NbPDS (345 bp + polyA)	NbPDSfor7 × NbPDSrev7

NbPDS (345 bp + polyG)	NbPDSfor7 × NbPDSrev8


CAT item	Comorbidity	p value	Cumulative R2

Cough

 	None

Phlegm

 	None

Chest tightness

 	GERD (FSSG ≥ 8)	<0.001	0.0901

 	Depression (HAD-D ≥ 11)	0.0033	0.123

Breathlessness

 	GERD (FSSG ≥ 8)	<0.001	0.0705

 	Osteoporosis	0.0355	0.0876

Activity limitation

 	GERD (FSSG ≥ 8)	<0.001	0.0926

 	Depression (HAD-D ≥ 11)	<0.001	0.1452

 	Arrhythmia	0.0026	0.1773

 	Osteoporosis	0.0222	0.1954

Confidence to leave home

 	GERD (FSSG ≥ 8)	<0.001	0.0631

 	Depression (HAD-D ≥ 11)	<0.001	0.107

 	Osteoporosis	<0.001	0.1337

 	Hypertension	0.0109	0.1571

 	Arrhythmia	0.0445	0.1714

Sleep

 	Depression (HAD-D ≥ 11)	<0.001	0.0807

 	GERD (FSSG ≥ 8)	0.0033	0.1134

 	Anxiety (HAD-A ≥ 11)	0.01	0.1378

 	Arrhythmia	0.0404	0.153

Energy

 	GERD (FSSG ≥ 8)	<0.001	0.1191

 	Depression (HAD-D ≥ 11)	<0.001	0.1972

 	Arrhythmia	<0.001	0.2487

 	Anxiety (HAD-A ≥ 11)	0.0333	0.263


Sex

Birth weight in grams

Mother's highest level of education

Young adult's highest level of education

Full scale WISC-R

Verbal IQ WISC-R

Performance IQ WISC-R

General information WISC-R

Similarities WISC-R

Arithmetic WISC-R

Vocabulary WISC-R

Comprehension WISC-R

Picture completion WISC-R

Picture arrangement WISC-R

Block design WISC-R

Object assembly WISC-R

Coding WISC-R

RCPM

ADHD rating scale inattentive score

ADHD rating scale hyperactivity/impulsivity score

ADHD rating scale total score

YASR attention problems


Variables	N (%)

Experienced an occupational injury	13 (32.5)

Knows other workers who have been injured	21 (52.5)

Major types of injury (N = 13)

Broken bone	3 (23.1)

Inhalation	3 (23.1)

Accidental injection/needle stab	3 (23.1)

Muscle sprain or strain	3 (23.1)

Part of body injured

Leg, knee, or hip	4 (30.8)

Hand or wrist	3 (23.1)

Eyes	2 (15.4)

Head or neck	1 (7.7)

Back	1 (7.7)

Arms or shoulders	1 (7.7)

Fingers	1 (7.7)

Cause of injury

Animal	10 (76.9)

Machine	2 (15.4)

Other	1 (7.7)

Lost time due to injury

No time lost	8 (61.5)

2-6 days lost	1 (7.7)

More than 30 days lost	4 (30.8)

Have health problems due to working with hogs	11 (28.2)

Type of occupational health problems

Allergies	3 (7.5)

Asthma	2 (5.0)

Bronchitis	2 (5.0)

Coughing	7 (17.5)

Eyes burning	10 (25.0)

Headaches	7 (17.5)

Hearing problems	2 (5.0)

Infections	1 (2.5)

Muscular pain	9 (22.5)

Nausea	4 (10.0)

Nasal congestion	4 (10.0)

Sneezing	6 (15.0)

Skin disorders	1 (2.5)

Pain in throat	3 (7.5)

Variables	N (%)

Experienced an occupational injury	13 (32.5)

Knows other workers who have been injured	21 (52.5)

Major types of injury (N = 13)

Broken bone	3 (23.1)

Inhalation	3 (23.1)

Accidental injection/needle stab	3 (23.1)

Muscle sprain or strain	3 (23.1)

Part of body injured

Leg, knee, or hip	4 (30.8)

Hand or wrist	3 (23.1)

Eyes	2 (15.4)

Head or neck	1 (7.7)

Back	1 (7.7)

Arms or shoulders	1 (7.7)

Fingers	1 (7.7)

Cause of injury

Animal	10 (76.9)

Machine	2 (15.4)

Other	1 (7.7)

Lost time due to injury

No time lost	8 (61.5)

2-6 days lost	1 (7.7)

More than 30 days lost	4 (30.8)

Have health problems due to working with hog	1

Variables	N (%)

s	1 (28.2)

Type of occupational health problems

Allergies	3 (7.5)

Asthma	2 (5.0)

Bronchitis	2 (5.0)

Coughing	7 (17.5)

Eyes burning	10 (25.0)

Headaches	7 (17.5)

Hearing problems	2 (5.0)

Infections	1 (2.5)

Muscular pain	9 (22.5)

Nausea	4 (10.0)

Nasal congestion	4 (10.0)

Sneezing	6 (15.0)

Skin disorders	1 (2.5)

Pain in throat	3 (7.5)


Disease	Trimester	Aminotransferases	Bilirubin	INR	Treatment	Prognosis*

Hyperemesis gravidarum	First	Up to 2-3 times upper limit of normal	<4	Always normal	Supportive	Excellent

Intrahepatic cholestasis of pregnancy	Second/third	Elevated sometimes rarely >1000	Elevated but <6	Typically normal	Ursodeoxycholic acid	Good

AFLP	Third	Elevated usually <1000	Elevated	Usually elevated	Delivery	Guarded

HELLP	Third	Elevated, variable, 5-20 times upper limit of normal	>1.2	Sometimes elevated	IV magnesium, BP control, delivery	Guarded

Acetaminophen	Any	>50 times upper limit of normal	Elevated usually <10	Usually elevated	NAC	Good if NAC administered promptly

Ischemia	Any	>50 times upper limit of normal	Elevated usually <4	Usually elevated (<3)	Supportive	Variable, depends on underlying disease

Viral	Any	>25 times upper limit of normal	Elevated	Variable	Supportive	Variable

Drug-induced	Any	>25 times upper limit of normal	Elevated	Variable	Supportive	Variable

Autoimmune	Any	5-10 times upper limit of normal	Normal	Variable	Corticosteroids, azathioprine	Variable


Scenario	Skin Area	Months	Time

S1	35% (face, hands, forearms, lower legs)	March–September	Constant

S2	35% (face, hands, forearms, lower legs)	June–August	Constant

10% (face and hands)	March–May, September

S3	10% (face and hands)	March–September	Constant

S4	35% (face, hands, forearms, lower legs)	June–August	Varies with latitude (equivalent to 1 SED) *

Scenario	Skin Area	Months	Time

S4	35% (face, hands, forearms, lower legs)	June–August	Varies with latitude (equivalent to 1 SED) *


Affective words	Answer	Categories of associated words

		Synonyms	Antonym	Life event	Relative behavior	Others

Happiness	Number	36	2	42	7	3

	Frequency (%)	40.45	2.24	47.19	7.87	3.37

Sadness	Number	21	0	47	17	4

	Frequency (%)	23.60	0	52.81	19.10	4.49

Anger	Number	25	1	45	10	8

	Frequency (%)	28.09	1.12	50.56	11.24	8.99

Fear	Number	29	0	52	6	1

	Frequency (%)	32.58	0	58.43	6.74	1.12


country	summarized area characteristics	number of species	references

Africa	continent-wide estimate (insects only)	600	DeFoliart (1992)

Africa	sub-Saharan Africa (insects only)	250	van Huis (2003)

Africa	Central and West Africa (plants only)	1500	Chege (1994)

Botswana	Tyua grow crops and use wild plants, animals, birds, fish and insects	171	Hitchcock (1999)

Congo	Mbuti Pygmies of forest: cultivators of cassava and plantain plus users of 230 animal and 100 plant species	330	Ishikawa (1999)

Ethiopia	subsistence agriculture, animal husbandry, semi-arid to humid	44	Fentahun & Hager (2009)

Ethiopia	country-wide estimate	203	Asfaw & Tadesse (2001)

Ethiopia	country-wide estimate	300	Asfaw (2009)

Ethiopia	agricultural, arid, open woodland (50% of plants in region edible)	25	Becker (1983)

Ethiopia	humid to semi-arid; forest to savannah, three ethnic groups in south Ethiopia	66	Balemie & Kebebew (2006)

Kenya	country-wide estimate for agricultural communities (plants only)	800	Maundu (1996)

Kenya	Turkana agro-pastoralists and rural fishing communities, arid and semi-arid	14	Levine & Crosskey (2006)

Madagascar	forest-dwelling, swidden cultivation in tropical forest	150	Styger et al. (1999)

Namibia	agriculture and livestock; tropical wetland, swamp and woodland in Caprivi	21	Mulonga (2003)

Nigeria	agricultural, savanna, semi-arid	121	Harris & Mohammed (2003)

Tanzania	agricultural, tropical forest, East Usambara mountains	28	Kessey (1998)

Tanzania	agricultural, tropical forest, East Usambara mountains	46	Hårkönen & Vainio-Mattila (1998)

Tanzania	Batemi agropastoralists, semi-arid (with 35 wild species cultivated)	44	Johns et al. (1996)

Uganda	agricultural households in southwest Uganda (some wild species cultivated and gathered from the wild)	94	Musinguzi et al. (2006)

Zambia	country-wide estimate	15–25	Pegler & Piearce (1980)


Summary of clinical data of the study group consisting of colon cancer patients, pre-malignant adenoma patients and healthy control patients

Parameter	Value	Colon cancer (CC) patients	Healthy control (H) patients	Adenoma (A) patients	P-value

 	 	(n = 164)	(n = 119)*	(n = 34)

Sex	Female	68 (41.5%)	67 (56.3%)	16 (47.1%)	0.738

 	Male	96 (58.5%)	52 (43.7%)	18 (52.9%)

Age	Range	40.5 – 99.1	19.5 – 90.8	28.1 – 86.1	0.144 (A vs H)

(years)	Mean	69.59	62.41	63.65	0.004 (CC vs H)


Gene	Primer	Sequence	Annealing temperature/elongation time	Literature

16S, rrnA	pF1	AGAGTTTGATCCTGGCTCAG	55°C/60 sec	[32]

 	pR4	CCAGCAGCCGCGGTAATAC	 	[33]

sodA	sodA-F	TRCAYCATGAYAARCACCAT	50°C/60 sec	[34]

 	sodA-R	ARRTARTAMGCRTGYTCCCARACRTC	 	[34]

groEL	StreptogroELd	GAHGTNGTIGAAGGIATGCA	52°C/60 sec	[35]

 	StreptogroELr	ATTTGRCGIAYWGGYTCTTC	 	[35]

gdh	GDHsoralisF	ATGGACAAACCAGCTAGCTT	55°C/60 sec	[6]

 	GDHsoralisR	GCTTGTGGTCCCATGCTTCC	 	[6]

gtfR	gtfRSoralisF	TCCCGGTCAGCAAACTCCAGCC	52°C/60 sec	[36]

 	gtfRSoralisR	GCAACCTTTGGATTTGCAAC	 	[36]

cshA-like	CshA-F	AAGTACAAGGTGCAGATG	46°C/40 sec	This study

 	CshA-R	CATTTGCAGTAGCTATCG	 	This study

rib-like	RibF	GTGACYTACCCAGATGG	47°C/30 sec	This study

 	RibR1	CAATWGAATCTTCWGCC	 	This study

pitA-like	pitAF	ATTWSTCCAATTCAGGGGC	55°C/45 sec	This study

 	pitAR	AATGCCCGCGTCCATACC	 	This study

integrase	InGraF	CTCATGATGTCAAAGAG	46°C/40 sec	This study

 	InGraR	GATTTGGAAYCGTGTGG	 	This study

hylA-like	hylAF	CAGCAAAGGGATGCCAAG	60°C /60 sec	This study

 	hylAR	CCTTCCAGTTCCTGGTTTAAC	 	This study

Tigurinus 16S, rRNA	TIGFCTT	AGAACGCTGAAGCTTGGT	55°C /30 sec	This study

 	TIGFAGA	GTAGAACGCTGAAGAGAGG	 	This study

 	TIGR	ATTATCATGCGATAATCAATT	 	This study

Mitis-group sodA	sodA-MSF	GCMAAYGCAGCTCTTGAA	58°C /35 sec	This study

 	sodA-MSR	ACCAACCAHGCCCATCCA	 	This study

Gene	Primer	Sequence	Annealing temperature/elongation time	Literature

	sodA-R	ARRTARTAMGCRTGYTCCCARACRTC		[34]

groEL	StreptogroELd	GAHGTNGTIGAAGGIATGCA	52°C/60 sec	[35]

	StreptogroELr	ATTTGRCGIAYWGGYTCTTC		[35]

gdh	GDHsoralisF	ATGGACAAACCAGCTAGCTT	55°C/60 sec	[6]

	GDHsoralisR	GCTTGTGGTCCCATGCTTCC		[6]

gtfR	gtfRSoralisF	TCCCGGTCAGCAAACTCCAGCC	52°C/60 sec	[36]

	gtfRSoralisR	GCAACCTTTGGATTTGCAAC		[36]

cshA-like	CshA-F	AAGTACAAGGTGCAGATG	46°C/40 sec	This study

	CshA-R	CATTTGCAGTAGCTATCG		This study

rib-like	RibF	GTGACYTACCCAGATGG	47°C/30 sec	This study

	RibR1	CAATWGAATCTTCWGCC		This study

pitA-like	pitAF	ATTWSTCCAATTCAGGGGC	55°C/45 sec	This study

	pitAR	AATGCCCGCGTCCATACC		This study

integrase	InGraF	CTCATGATGTCAAAGAG	46°C/40 sec	This study

	InGraR	GATTTGGAAYCGTGTGG		This study

hylA-like	hylAF	CAGCAAAGGGATGCCAAG	60°C /60 sec	This study

	hylAR	CCTTCCAGTTCCTGGTTTAAC		This study

Tigurinus 16S, rRNA	TIGFCTT	AGAACGCTGAAGCTTGGT	55°C /30 sec	This study

	TIGFAGA	GTAGAACGCTGAAGAGAGG		This study

	TIGR	ATTATCATGCGATAATCAATT		This study

Mitis-group sodA	sodA-MSF	GCMAAYGCAGCTCTTGAA	58°C /35 sec	This study

	sodA-MSR	ACCAACCAHGCCCATCCA		This study


GR Operation	Operation Zone	Total Population	Total Populated Households	Total Households	Total Structures

GR1:Outer Islands, Temotu Province	Duff Islands	556	118	158	399

	Reef Islands	5958	1179	1468	3746

	Utupua	1300	259	330	770

	Vanikolo	1602	308	399	938

	GR1: Total	9416	1864	2355	5853

GR2: Santa Cruz, Temotu Province	Santa Cruz East	3950	717	881	1873

	Santa Cruz West	8162	1563	1970	4046

	GR2: Total	12112	2280	2851	5919

GR3: Tanna IRS Zone, Tafea Province	Health Zone 1	5363	1064	1283	5214

	Health Zone 2	9395	1863	2196	7299

	Health Zone 3	3096	653	773	2923

	Health Zone 4	4115	866	1001	3455

	GR3: Total	21969	4446	5253	18891

GR Operation	Operation Zone	Total Population	Total Populated Households	Total Households	Total Structures

GR1:Outer Islands, Temotu Province	Duff Islands	556	118	158	399

	Reef Islands	5958	1179	1468	3746

	Utupua	1300	259	330	770

	Vanikolo	1602	308	399	938

	GR1: Total	9416	1864	2355	5853

GR2: Sant	Santa C	3950	71	88

GR Operation	Operation Zone	Total Population	Total Populated Households	Total Households	Total Structures

a Cruz, Temotu Province	ruz East		7	1	1873

	Santa Cruz West	8162	1563	1970	4046

	GR2: Total	12112	2280	2851	5919

GR3: Tanna IRS Zone, Tafea Province	Health Zone 1	5363	1064	1283	5214

	Health Zone 2	9395	1863	2196	7299

	Health Zone 3	3096	653	773	2923

	Health Zone 4	4115	866	1001	3455

	GR3: Total	21969	4446	5253	18891


	ENINBSC study	CRONICAS study

	(n = 2,472)	(n = 2,945)

Demographic variables

Sex (% females)	1,209 (48.9%)	1,500 (50.9%)

Age (mean (SD))	50.5 (12.1)	55.3 (12.7)

Education in years (mean (SD))	7.8 (4.9)	8.0 (4.9)

Behavioural variables

Current smoking (%)	391 (15.9%)	369 (11.5%)

Al	2,323 (9	1,600 (5


Gene		Sequence	Product size	Annealling temperature

MMP-2	Sense	5'-GGATGATGCCTTTGCTCG-3'	487 bp	55°C

	Anti-sense	5'-ATAGGATGTGCCCTGGAA-3'

MMP-7	Sense	5'-CTTCAGGCAGAACATCCA-3'	220 bp	49°C

	Anti-sense	5'-ATTTATTGACATCTACCCAC-3'

MMP-9	Sense	5'-AGGACGGCAATGCTGATC-3'	127 bp	58°C

	Anti-sense	5'-TCGTAGTTGGCGGTGGTG-3'

MT1-MMP	Sense	5'-CCTGCGTCCATCAACACT-3'	481 bp	57°C

	Anti-sense	5'-TCACCTCCGTCTCCTCCTC-3'

SFRP5	Sense	5'-AGGGTAAGGGAAAGGTGGAG-3'	379 bp	60°C

	Anti-sense	5'-GAGAAGCAGAGGCTGAGGAA-3'

GAPDH	Sense	5'-GGGAAACTGTGGCGTGAT-3'	309 bp	56°C

	Anti-sense	5'-AAAGGTGGAGGAGTGGGT-3'

Gene		Sequence	Product size

MMP-2	Sense	5'-GGATGATGCCTTTGCTCG-3'	487 bp

	Anti-sense	5'-ATAGGATGTGCCCTGGAA-3'

MMP-7	Sense	5'-CTTCAGGCAGAACATCCA-3'	220 bp

	Anti-sense	5'-ATTTATTGACATCTACCCAC-3'

MMP-9	Sense	5'-AGGACGGCAATGCTGATC-3'	127 bp

	Anti-sense	5'-TCGTAGTTGGCGGTGGTG-3'

MT1-MMP	Sense	5'-CCTGCGTCCATCAACACT-3'	481 bp

	Anti-sense	5'-TCACCTCCGTCTCCTCCTC-3'

SFRP5	Sense	5'-AGGGTAAGGGAAAGGTGGAG-3'	379 bp

	Anti-sense	5'-GAGAAGCAGAGGCTGAGGAA-3'

GAPDH	Sense	5'-GGGAAACTGTGGCGTGAT-3'	309 bp

	Anti-sense	5'-AAAGGTGGAGGAGTGGGT-3'

Annealling temperature

55°C

49°C

58°C

57°C

60°C

56°C


Variables	No. of cases	NQO1 strongly positive cases (%)	χ2	Pvalue

Age			0.161	0.689

≥48	97	57 (58.8%)

<48	63	35 (55.6%)

Menopausal status			0.050	0.823

Premenopausal	76	43 (56.6%)

Postmenopausal	84	49 (58.3%)

Histological grade			19.056	0.000**


Community	Type	MBR Culex spp.	MBR A. gambiae s.l.	EIR A. gambiae s.l.

Ushertown	U	36.9 (16.6–81.9)	1.1 (1.0–1.2)	2.57


Year	First author	Type of study	Number and type of patients considered	Patients with solitary splenic metastases from NPC	Patient’s age, sex (M, F)	Comorbidity	Primary treatment for NPC	Disease-free survival after primary treatment	Methods of detection of splenic metastasis	Treatment for solitary splenic metastasis	Confirmatory histology of NPC splenic metastases	Overall survival (status at last follow-up)	Relapse after splenic surgery

2000	Lam & Tang [3]	CS	92 patients with splenic metastases	1 (1.1 %)	M	NS	NS	NS	NS	- Splenectomy	UCNT	NS	NS

2013	Suh et al. [38]	CR	1 non-keratinizing NPC	1	35 years old, M	EBV	- Neoadjuvant chemotherapy (cysplatin and 5-fluorouracil)- Left medial maxillectomy with left modified radical neck dissection- Adjuvant radiochemotherapy (cysplatin and 63 Gy)	7 months	FDG-PET/CT FNA biopsy	- Systemic chemotherapy (docetaxel and cysplatin)- Laparoscopic splenectomy	UCNT	5 months (alive)	Nil

2015	Abu-Zaid et al. [27]	CR	1 NPC	1	26 years old, M	NS	- Surgical resection- Adjuvant radiochemotherpay	6 years	CTFNA biopsy	- Splenectomy	UCNT	12 months (alive)	Nil

2015	Present study	CR	1 NPC	1	56 years old, M	Smoker, EBV	- Neoadjuvant chemotherapy (docetaxel, carboplatin, and 5-Fluorouracil)- Radiotherapy (70 Gy)	3 months	PET/CT	- Laparoscopic splenectomy	UCNT	4 months (alive)	Nil

Year	First author	Type of study	Number and type of patients considered	Patients with solitary splenic metastases from NPC	Patient’s age, sex (M, F)	Comorbidity	Primary treatment for NPC	Disease-free survival after primary treatment	Methods of detection of splenic metastasis	Treatment for solitary splenic metastasis	Confirmatory histology of NPC splenic metastases	Overall survival (status at last follow-up)	Relapse after splenic surgery

2000	Lam & Tang [3]	CS	92 patients with splenic metastases	1 (1.1 %)	M	NS	NS	NS	NS	- Splenectomy	UCNT	NS	NS

2013	Suh et al. [38]	CR	1 non-keratinizing NPC	1	35 years old, M	EBV	- Neoadjuvant chemotherapy (cysplatin and 5-fluorouracil)- Left medial maxillectomy with left modified radical neck dissection- Adjuvant radiochemotherapy (cysplatin and 63 Gy)	7 months	FDG-PET/CT FNA biopsy	- Systemic chemotherapy (docetaxel and cysplatin)- Laparoscopic splenectomy	UCNT	5 months (alive)	Nil

2015	Abu-Zaid et al. [27]	CR	1 NPC	1	26 years old, M	NS	- Surgical resection- Adjuvant radiochemotherpay	6 years	CTFNA biopsy	- Splenectomy	UCNT	12 months (alive)	Nil

2015	Present stud	CR	1 	1	56 y		- Neoadjuvant chemotherapy (docetaxel, carboplatin, and 5-Fluorouracil)- Radiotherap	3 m		- Lap	U	4 months	N

y		NPC		ears old, M	Smoker, EBV	y (70 Gy)	onths	PET/CT	aroscopic splenectomy	CNT	 (alive)	il


Health Effects	US	EU	Canada	Australia	New Zealand

Mortality:			1,042		1,296,552 (premature death) [198]

VSL: Adults	6,300,000	2,247,191	3,480,000	1,439,394	1,717,241 (1,724,138) [198]

VSL: Children	2 × adult	4088764 (infant)

VSLY		134,831		70,455	118,621

Morbidity:				1929.55 (average cost/separation) [199]

Morbidity: children	2 × adults

Chronic bronchitis	340,000	213,483

Chronic asthma	39,000

Respiratory hospital admission	14,000	2,247	1,032		2,069

CVD hospital admission	21,000	2,247	1,052		2,759

Emergency room visit	300 (asthma)		541 (respiratory) 562 (CVD)

Doctor's visit		60

RAD	106	92 (working age) 78 (young, elderly)	22		53

MRAD	50	43

Acute respiratory symptom	3–24

Use of respiratory medication		1.12

Asthma day	32–74	43	15

References:	[54]	[127]	[200]	[128]*	[129]

Health Effects	US	EU	Canada	Australia	New Zealand

RAD	106	92 (working age) 78 (young, elderly)	22		53

MRAD	50	43

Acute respiratory symptom	3–24

Use of respiratory medication		1.12

Asthma day	32–74	43	15

References:	[54]	[127]	[200]	[128]*	[129]


Non-Misusers	Misusers	p-value	RR (95% CI)


Register	Data available	Register holder	Ref.

Medical Birth Register	Mother’s health data (incl. Smoking habits prior to and during pregnancy, other risk factors, interventions), pregnancy, delivery, live and stillbirths, GD, BMI, infant health data by age of 7 days	THL	[30]

Register of Induced Abortions	Data on mother, indication for induced abortion, diagnoses	THL	[38]

Register of Congenital Malformations	Mother’s health data, pregnancy, foetus/child, congenital anomalies and birth defects, diagnoses (ICD codes)	THL	[31]

Care Register for Health Care	Data from hospitals and special health care, diagnoses	THL	[33]

Register of Primary Health Care Visits	Data outpatient health care visits, diagnoses (available since 2011)	THL	[34]

Cancer Register	Persons with cancer, data on cancer type and death certificate	THL	[32]

Cause-of-Death Register	Causes of death, death certificates	Statistics Finland	[36]

Register of reimbursements for Prescription Medicines	Purchases of prescription medication eligible for reimbursement	KELAa	[35]

Finnish Maternity Cohort	Serum bank, data on mother, sampling date, expected due date, previous pregnancies	THLb	[42]

Population Register	Address history	Population Register Center	[37]

Register	Data available	Register holder	Ref.

Medical Birth Register	Mother’s health data (incl. Smoking habits prior to and during pregnancy, other risk factors, interventions), pregnancy, delivery, live and stillbirths, GD, BMI, infant health data by age of 7 days	THL	[30]

Register of Induced Abortions	Data on mother, indication for induced abortion, diagnoses	THL	[38]

Register of Congenital Malform	Mother’	TH	[

ations	s health data, pregnancy, foetus/child, congenital anomalies and birth defects, diagnoses (ICD codes)	L	31]

Care Register for Health Care	Data from hospitals and special health care, diagnoses	THL	[33]

Register of Primary Health Care Visits	Data outpatient health care visits, diagnoses (available since 2011)	THL	[34]

Cancer Register	Persons with cancer, data on cancer type and death certificate	THL	[32]

Cause-of-Death Register	Causes of death, death certificates	Statistics Finland	[36]

Register of reimbursements for Prescription Medicines	Purchases of prescription medication eligible for reimbursement	KELAa	[35]

Finnish Maternity Cohort	Serum bank, data on mother, sampling date, expected due date, previous pregnancies	THLb	[42]

Population Register	Address history	Population Register Center	[37]


Serogroup	Serotype	Serosubtype	Number	Percentage

B	1	P1.4	4	1.8

		P1.16	4	1.8

		NT	3	1.4

		Other	1	0.5

	2A		3	1.4

	4	P1.4	57	26

		P1.6	3	1.4

		P1.7	3	1.4

		P1.9	4	1.8


	Number (%)	Number (%) with smear completion rate <90%	Bivariable Odds Ratioa	95%CI	Pb	Multi-variable Odds Ratioa	95%CI	Pb

Overall	88 (100%)	43 (48.9%)

Category of health facility					0.025

Health centre	69 (78.4%)	30 (43.5%)	1

Hospital	19 (21.6%)	13 (68.4%)	2.0	1.1-3.7

Location of health facility					0.008

Rural	60 (68.2%)	25 (41.7%)	1

Urb	2			1.2-


Muscle	Mean polarization

WT-RLC (standard)	0.321 ± 0.033

A13T-non-mutated (standard)	0.314 ± 0.028

A13T-mutated (non-standard)	0.250 ± 0.037


		Frequency in patients: Percent (%)in four categories of severity

Severity of complaints	Population % Standard	<underline>Before</underline> therapy %	<underline>After</underline> therapy %

Total score

No or little (-4)	48	26.4	86.8

Mild (5–8)	25	18.2	8.4

Moderate (9–15)	20	27.8	4.0

Severe (16+)	8	27.6	0.8

Psychological score

No or little (-1)	48	30.7	82.5

Mild (2–3)	23	17.0	10.4

Moderate (4–6)	20	22.2	5.5

Severe (7+)	9	30.1	1.6

Somatic score

No or little (-2)	53	35.7	93.0

Mild (3–4)	24	22.7	5.1

Moderate (5–7)	15	25.5	1.6

Severe (8+)	8	16.1	0.3

Sexual score

No or little (0)	64	37.3	76.8

Mild (1)	13	13.3	11.6

Moderate (2–3)	16	22.2	8.7

Severe (4+)	7	27.3	2.9

		Frequency in patients: Percent (%)in four categories of severity

Severity of complaints	Population % Standard	Before therapy %	After therapy %

Total score

No or little (-4)	48	26.4	86.8

Mild (5–8)	25	18.2	8.4

Moderate (9–15)	20	27.8	4.0

Severe (16+)	8	27.6	0.8

Psychological score


Attributes	SED Group	SEA Group	Unadjusted

	Na	%	Na	%	OR (95% CI)

SOCIODEMOGRAPHIC

Marital Status	213		424

 Has partner		79		99	0.05 (0.02–0.13)

Education	212		432

 Less than high school		25		5	2.25 (1.93–2.63)

Cultural Identity	211		428

 Canadian		50		61	0.61 (0.44–0.85)

Language Spoken at Home	217		431

 English		63		82	0.37 (0.26–0.49)

Country of Birth	215		421

 Canada		45		70	0.35 (0.25–0.49)

WOMAN'S HEALTH

Overall Health	215		431

 Very good/Excellent		41		59	0.48 (0.35–0.67)

Symptoms of Postpartum Depression	211		426

 EPDS ≥ 12		19		8	2.7 (1.64–4.4)

Hospital Readmission	216		431

 YES		3		2	1.57 (0.57–4.28)

PHYSICIAN

Has Family Doctor	215		430

 YES		96		97	0.74 (0.3–1.84)

Attributes	SED Group	SEA Group	Unadjusted

	Na	%	Na	%	OR (95% CI)

IAN

Has Family Doctor	215		430

YES		96		97	0.74 (0.3–1.84)


Compounds	Range (ng/mL)	Linear regression equation	Correlation coefficient	LOD (ng mL−1)	LOQ (ng mL−1)

Nootkatone	2.00-1000.00	Y = 5910X + 2790	0.9979	0.60	2.00

Yakuchinone A	2.00-1000.00	Y = 7090X + 12100	0.9997	0.60	2.00

Yakuchinone	2.00-1000.	Y = 8100	0	0


Image	Diameter Measurement Method	Error (%) Relative to MD in Image LS

Min	Average	Max

LS	MAL-F2	0.1	1.2	3.8

MD	0.5	5.8	16

IS	MAL-F1	0.8	5.6	12.2

MAL-F2	0.2	15.0	60.5


Predictive factor	Vaccination document	At least one vaccine dose	Minimum vaccination	Basic vaccination	Extended vaccination	MMR1

Weighted percent (%)a (95% CI) b	Weighted percent (%)a (95% CI)b	Weighted percent (%)a (95% CI)b	Weighted percent (%)a (95% CI)b	Weighted percent (%)a (95% CI)b	Weighted percent (%)a (95% CI)b

Gender	n = 250	n = 239	n = 239	n = 239	n = 239	n = 239

Male	89 (81–94)	79 (70–86)	31 (20–44)	26 (17–37)	17 (10–29)	38 (27–51)

Female	83 (67–92)	83 (67–92)	39 (27–52)	30 (18–44)	11 (4–23)	48 (37–58)

P value	0.3143	0.5779	0.2558	0.5160	0.0587	0.1706


Characteristic	Entire cohort	By distance (m) to nearest A1–A3 roadway (m)b

≥ 200	51–199	0–50

Age (years)c	42.0 ± 5.1	42.1 ± 5.1	41.9 ± 5.2	42.0 ± 5.3

BMI (kg/m2)	25.9 ± 6.0	25.8 ± 5.9	26.0 ± 6.1	26.4 ± 6.4

Census tract median income ($10,000)	6.68 ± 2.38	6.75 ± 2.29	6.66 ± 2.47	6.33 ± 2.56

Census tract median home value ($100,000)	1.72 ± 1.24	1.67 ± 1.08	1.84 ± 1.41	1.76 ± 1.57

Caucasian race	94	94	93	93

Age at menarche (years)

< 12	23	23	23	23

12	30	30	30	31

> 12	46	47	46	46

Parity

Nulliparous	18	16	21	25

Parous	82	84	79	75

Oral contraception use

Never	14	13	16	15

Past	75	75	73	74

Current	10	10	10	10

Cigarette smoking

Never	67	68	66	65

Current	9	8	10	10

Former	24	24	24	24

Infertility

Yes	4	4	4	4

No	94	94	94	94

Ever performed rotating shift work

Yes	69	69	69	70

No	31	31	31	30

Region

Northeast	34	32	37	42

Midwest	34	35	31	30

West	15	14	20	15

South	17	19	13	13

Values are mean ± SD or percent. aValues are standardized to the age distribution of the study population. bEach cohort member may be in multiple distance categories over follow-up. cValues are not age-adjusted

Characteristic	Entire cohort	By distance (m) to nearest A1–A3 roadway (m)b

≥ 200	51–199	0–50

Northeast	34	32	37	42

Midwest	34	35	31	30

West	15	14	20	15

South	17	19	13	13

Values are mean ± SD or percent. aValues are standardized to the age distribution of the study population. bEach cohort member may be in multiple distance categories over follow-up. cValues are not age-adjusted


	Team response1	Individual response

	Number of teams analysed	Number of questionnaires send	Number of questionnaires returned	Number of questionnaires analysed

Internal medicine	11	142	127	115

Surgery	10	83	77	69

Radiology	7	45	42	42

Total	28	270	246	226

	Team response1	Individual response

	Number of teams analysed	Number of questionnaires send	Number of questionnaires returned	Number of questionnaires analysed

Internal medicine	11	142	127	115

Surgery	10	83	77	69

Rad	7			42

	Team response1	Individual response

iology		45	42

Total	28	270	246	226


Query	SQL	SQL	SPARQL	SPARQL

	count	time	count	time

	result		result

Recovery all Patients	207.190	0,060s	207.190	0,189s

Recovery all Therapies	400.290	0,132s	400.290	0,317s

Recovery all Diagnosis	240.088	0,070s	240.088	0,220s

Recovery all Courses	108.297	0,030s	108.297	0,155s

Recovery patients with diagnosis, therapies and courses	207.190	1,048s	207.190	0,204s

Recovery all female Patients	105.714	0,231s	105.714	0,189s

Recovery all female Patients with more of 60 years old	62.603	0,245s	62.603	0,192s

Query	SQL

	count

	result

Recovery all Patients	207.190

Recovery all Therapies	400.290

Recovery all Diagnosis	240.088

Recovery all Courses	108.297

Recovery patients with diagnosis, therapies and courses	207.190

Recovery all female Patients	105.714

Recovery all female Patients with more of 60 years old	62.603


Jeddah A	Val68Met+Asn126Asp+Ser188Phe

Jeddah B	Val68Met+Ser188Phe

Jeddah C	Asn126Asp+Ser188Phe

Jeddah D	Ile48Thr+Val68Met

Jeddah E	Ile48Thr+Ser188Phe

Jeddah A	Val68Met+Asn126Asp+Ser188Phe

Jeddah B	Val68Met+Ser188Phe

J	Asn126Asp+Ser188Ph

Jeddah A	Val68Met+Asn126Asp+Ser188Phe

eddah C	e

Jeddah D	Ile48Thr+Val68Met

Jeddah E	Ile48Thr+Ser188Phe


Days with Instrument	Clear Nights (N = 2,379)	MEA < 0° (N = 7,952)	All Nights (N = 13,790)


NHANES, FPED Dataset 1	USDA-ERS Dataset 2

Total meat	Total meat, fish, eggs and nuts

 Meat Cured Meat Poultry Organ meat Seafood from high omega-3 sources Seafood from low omega-3 sources	 Total red meat Total Poultry Total fresh and frozen, canned, and cured fish and shellfish Eggs Peanuts Total tree nuts Coconut

Meat	Total red meat

 Beef Veal Pork Lamb Game meat	 Beef Veal Pork Lamb

Cured Meat	Category not included in dataset

 Cured or luncheon meat made from beef, pork or poultry

Poultry	Total poultry

 Chicken Turkey Cornish hens Game birds	 Chicken Turkey

* Two categories of Seafood	Total fresh and frozen, canned, and cured fish and Shellfish

 Seafood from high omega-3 sourcesFinfishShellfishOther seafood Seafood from low omega-3 sourcesFinfishShellfishOther seafood	 Total fresh and frozen fish and shellfishFresh and frozen fishFresh and frozen shellfish Total canned fish and shellfishCanned salmonCanned sardinesCanned tunaCanned shellfishOther canned fish Cured Fish

Other Categories in the dataset	Other Categories in the dataset

 Organ Meat	 Eggs

Organ meat from beef, veal, pork, lamb, game or poultry 	 Peanuts

 Total Tree nutsAlmondsHazelnutsPecansWalnutsMacadamia nutsPistachio nutsOther tree nuts

	 Coconut


Departments	Internal Medicine (n = 19)	Urology (n = 19)	Total (n = 38)

Number of beds, mean (SD)	67 (22)	18 (9)	43 (30)

% Female physicians, mean (SD)	33 (13)	17 (15)	25 (16)

Teaching hospital department*	17 (89)	12 (63)	29 (76)

Residents working at the department	19 (100)	16 (84)	35 (92)

Microbiological laboratory in the same building as the department	12 (63)	8 (42)	20 (53)

Reporting of a positive urine culture by phone (incidentally or structurally)	0	2 (11)	2 (5)

Structurala education on antibiotics for residents	14 (74)	4 (21)	18 (47)

Structural education on antibiotics for senior staff members	4 (21)	0	4 (11)

Audit and feedback (incidentallyb or structurally)

On antibiotic prescriptionsc, at the department level	2 (11)	8 (42)	10 (26)

On antibiotic prescriptionsc, at the individual level	0	2 (11)	2 (5)

On antibiotic resistance rates of the hospital	9 (47)	12 (63)	21 (55)

Individual advice (of microbiologist/ pharmacist/ infectious diseases (ID) physician), incidentally or structurally, regarding streamlining therapy on the basis of blood or urine culture result	16 (84)	16 (84)	32 (84)

Microbiologist and/or ID physician structurally present at ward rounds discussing antibiotic therapy	6 (32)	0	6 (16)

Quality improvement project concerning antibiotic prescribing in past 3 years	8 (42)	7 (37)	15 (40)

Changes in antibiotic procedures or policies in past 3 yearsd	13 (68)	14 (74)	27 (71)

Departments	Internal Medicine (n = 19)	Urology (n = 19)	Total (n = 38)

% Female physicians, mean (SD)	33 (13)	17 (15)	25 (16)

Teaching hospital department*	17 (89)	12 (63)	29 (76)

Residents working at the department	19 (100)	16 (84)	35 (92)

Microbiological laboratory in the same building as the department	12 (63)	8 (42)	20 (53)

Reporting of a positive urine culture by phone (incidentally or structurally)	0	2 (11)	2 (5)

Structurala education on antibiotics for residents	14 (74)	4 (21)	18 (47)

Structural education on antibiotics for senior staff members	4 (21)	0	4 (11)

Audit and feedback (incidentallyb or structurally)

On antibiotic prescriptionsc, at the department level	2 (11)	8 (42)	10 (26)

On antibiotic prescriptionsc, at the individual level	0	2 (11)	2 (5)

On antibiotic resistance rates of the hospital	9 (47)	12 (63)	21 (55)

Individual advice (of microbiologist/ pharmacist/ infectious diseases (ID) physician), incidentally or structurally, regarding streamlining therapy on the basis of blood or urine culture result	16 (84)	16 (84)	32 (84)

Microbiologist and/or ID physician structurally present at ward rounds discussing antibiotic therapy	6 (32)	0	6 (16)

Quality improvement project concerning antibiotic prescribing in past 3 years	8 (42)	7 (37)	15 (40)

Changes in antibiotic procedures or policies in past 3 yearsd	13 (68)	14 (74)	27 (71)


miRNA Name	Consensus Sequence	Fold Change

Up Regulated miRNAs	3 h	24 h

miR-129-5p	CUUUUUGCGGUCUGGGCUUGC	19.8	9.5

miR-200a-3p	UAACACUGUCUGGUAACGAUGU	15.9	8.8

miR-297	AUGUAUGUGUGCAUGUGCAUG	15.6	18.6

miR-200b-3p	UAAUACUGCCUGGUAAUGAUGA	14.7	10.2

miR-595	GAAGUGUGCCGUGGUGUGUCU	10.4	9.3

miR-574-5p	UGAGUGUGUGUGUGUGAGUGUGU	7.2	8.6

miR-647	GUGGCUGCACUCACUUCCUUC	4.1	5.0

miR-615-3p	UCCGAGCCUGGGUCUCCCUCUU	3.9	4.3

miR-1224-5p	GUGAGGACUCGGGAGGUGG	3.5	4.2

miR-1238-3p	CUUCCUCGUCUGUCUGCCCC	2.2	2.2

miR-196a-5p	UAGGUAGUUUCAUGUUGUUGGG	3.1	-

miR-616-3p	AGUCAUUGGAGGGUUUGAGCAG	3.9	-

miR-760	CGGCUCUGGGUCUGUGGGGA	3.7	-

miR-1275	GUGGGGGAGAGGCUGUC	2.1	-

miR-146a-5p	UGAGAACUGAAUUCCAUGGGUU	-	13.7

miR-631	AGACCUGGCCCAGACCUCAGC	-	12.6

miR-661	UGCCUGGGUCUCUGGCCUGCGCGU	-	7.7

miR-766-3p	ACUCCAGCCCCACAGCCUCAGC	-	4.6

miR-1273a	GGGCGACAAAGCAAGACUCUUUCUU	-	2.8

miR-1202	GUGCCAGCUGCAGUGGGGGAG	-	2.7

miR-943	CUGACUGUUGCCGUCCUCCAG	-	2.7

miR-1250-5p	ACGGUGCUGGAUGUGGCCUUU	-	2.6

miR-1229-3p	CUCUCACCACUGCCCUCCCACAG	-	2.5

Down Regulated miRNAs

miR-301b-3p	CAGUGCAAUGAUAUUGUCAAAGC	−3.3	−2.8

miR-548a-3p	CAAAACUGGCAAUUACUUUUGC	−3.1	−3.1

miR-377-3p	AUCACACAAAGGCAACUUUUGU	−2.1	−3.2

miR-602	GACACGGGCGACAGCUGCGGCCC	−2.1	-

miR-802	CAGUAACAAAGAUUCAUCCUUGU	−2.2	-

miR-376b-3p	AUCAUAGAGGAAAAUCCAUGUU	-	−2.9

miR-216b-5p	AAAUCUCUGCAGGCAAAUGUGA	-	−2.4

miR-216a-5p	UAAUCUCAGCUGGCAACUGUGA	-	−2.4

miR-410-3p	AAUAUAACACAGAUGGCCUGU	-	−2.3

miR-29b-3p	UAGCACCAUUUGAAAUCAGUGUU	-	−2.1

Consensus Sequence	Fold Change

Up Regulated miRNAs	3 h	24 h

CUUUUUGCGGUCUGGGCUUGC	19.8	9.5

UAACACUGUCUGGUAACGAUGU	15.9	8.8

AUGUAUGUGUGCAUGUGCAUG	15.6	18.6

UAAUACUGCCUGGUAAUGAUGA	14.7	10.2

GAAGUGUGCCGUGGUGUGUCU	10.4	9.3

UGAGUGUGUGUGUGUGAGUGUGU	7.2	8.6

GUGGCUGCACUCACUUCCUUC	4.1	5.0

UCCGAGCCUGGGUCUCCCUCUU	3.9	4.3

GUGAGGACUCGGGAGGUGG	3.5	4.2

CUUCCUCGUCUGUCUGCCCC	2.2	2.2

UAGGUAGUUUCAUGUUGUUGGG	3.1	-

AGUCAUUGGAGGGUUUGAGCAG	3.9	-

CGGCUCUGGGUCUGUGGGGA	3.7	-

GUGGGGGAGAGGCUGUC	2.1	-

UGAGAACUGAAUUCCAUGGGUU	-	13.7

AGACCUGGCCCAGACCUCAGC	-	12.6

UGCCUGGGUCUCUGGCCUGCGCGU	-	7.7

ACUCCAGCCCCACAGCCUCAGC	-	4.6

GGGCGACAAAGCAAGACUCUUUCUU	-	2.8

GUGCCAGCUGCAGUGGGGGAG	-	2.7

CUGACUGUUGCCGUCCUCCAG	-	2.7

ACGGUGCUGGAUGUGGCCUUU	-	2.6

CUCUCACCACUGCCCUCCCACAG	-	2.5

Down Regulated miRNAs

CAGUGCAAUGAUAUUGUCAAAGC	−3.3	−2.8

CAAAACUGGCAAUUACUUUUGC	−3.1	−3.1

AUCACACAAAGGCAACUUUUGU	−2.1	−3.2

GACACGGGCGACAGCUGCGGCCC	−2.1	-

CAGUAACAAAGAUUCAUCCUUGU	−2.2	-

AUCAUAGAGGAAAAUCCAUGUU	-	−2.9

AAAUCUCUGCAGGCAAAUGUGA	-	−2.4

UAAUCUCAGCUGGCAACUGUGA	-	−2.4

AAUAUAACACAGAUGGCCUGU	-	−2.3

UAGCACCAUUUGAAAUCAGUGUU	-	−2.1


Cohort and animal identifier	No. of SIV DNA copies per 106 cells	No. of SIV RNA copies per μg RNA	Brain MΦ-QVOA IUPM

Basal ganglia	Parietal cortex	Basal ganglia	Parietal cortex	Without wells (<50 copies/ml)	With wells (<50 copies/ml)

A1


Sample	Number of seeds per score category (n)

	No germination and seed coat infection (Score = n × 0)	Seed coat and radical tip infection (Score = n × 1)	Either seed coat or radical tip infection (Score = n × 2)	Healthy seed germination (Score = n × 3)	Total score

Control (+)	None	None	None	6	18

Control (-)	5	1	None	None	1

10 mg l-1	2	3	1	None	5

25 mg l-1	1	2	2	1	9

50 mg l-1	None	None	2	4	16

100 mg l-1	None	None	1	5	17

200 mg l-1	None	None	None	6	18


Learner	General practice	Hospital	Other	All

Doctors	43 (49%)	3 (3%)	-	46 (52%)

Nurses	16 (18%)	20 (23%)	4 (5%)	40 (45%)

Students	-	-	2 (2%)	2 (2%)

Learner	General practice	Hospital	Other	All

Doctors	43 (49%)	3 (3%)	-	46 (52%)

Nurse	16 (18%)	20 	4 	4

Learner	General practice	Hospital	Other	All

s		(23%)	(5%)	0 (45%)

Students	-	-	2 (2%)	2 (2%)


AMP family	D. melanogaster gene	HMM state	Induction	Average Coverage (Naïve)	Average Coverage (Infected)

Attacins	AttA	strongly induced	21.59	1.33	38.37

	AttB	strongly induced	23.23	2.26	70.20

	AttC	strongly induced	35.90	0.96	46.29

	AttD	ND1

Cecropins	CecA1	strongly induced	27.33	1.18	43.20

	CecA2	strongly induced	43.80	0.68	39.59

	CecB	ND

	CecC	ND

Defensins	Def	moderately induced	3.35	7.68	34.40

Diptericins	Dpt	strongly induced	80.26	2.99	320.51

	DptB	strongly induced	Inf	0.00	30.37

Metchnikowin	Mtk	strongly induced	23.47	7.94	249.23

Drosocin	Dro	strongly induced	17.07	28.03	640.13

Drosomycins	Drs	strongly induced	6.99	19.28	180.39

	Dro2	ND

	Dro3	ND

	Dro4	not regulated	0.95	12.74	10.00

	Dro5	ND

	Dro6	ND

	Drs-l	ND


	Home safety only (n = 15)	Home safety + Home exercise (n = 15)

OT	OT	Peer mentor


 	Artificial data	Biological data

Scenario characteristics	1st design	2nd design	1st design	2nd design

Total cost / expectation	97443.4	151629.7	210917.0	535524.0

Total cost / expectation of gains	60.0	358.4	53448.0	77040.5

Total cost / expectation of losses	38024.0	56660.0	98376.0	187600.5

Total cost / expectation of duplications	26796.0	34324.6	38286.0	44639.6

Total cost / expectation of transfers	32563.4	60168.3	17887.0	223854.8

Total cost / expectation of the gain_big events	0.0	118.4	2920.0	2388.6

Running time	<1m	2m	15m	41m

Scenario characteristics

Total cost / expectation

Total cost / expectation of gains

Total cost / expectation of losses

Total cost / expectation of duplications

Total cost / expectation of transfers

Total cost / expectation of the gain_big events

Running time


Characteristics	Number	Percent

Age group (years)

 14–24	44	18.0

 25–34	54	22.1

 35–44	124	50.8

 45 and above	22	9.0

 Total	244	100

Highest educational level

 Primary	14	5.7

 Junior High School	64	26.2

 Senior High School	54	22.1

 Tertiary	96	39.3

 Post-Graduate	14	5.7

 Uneducated	2	0.8

 Total	244	100

Tribe

 Akan	112	45.9

 Ewe	58	23.8

 Ga	44	18.0

 Northern	30	12.3

 Total	244	100

Parity

 Zero	156	63.9

 1 and above	88	36.1

 Total	244	100

Body Mass Index

 <25	76	31.1

 25–29.9	78	32.0

 30 and above	90	36.9

 Total	244	100

Menstrual flow pattern (heavy flow)

 Yes	102	41.8

 No	142	58.2

 Total	244	100

Type of menstrual cycle (irregular)

 Yes	164	67.2

 No	80	32.8

 Total	244	100

Characteristics	Number

Age group (years)

14–24	44

25–34	54

35–44	124

45 and above	22

Total	244

Highest educational level

Primary	14

Junior High School	64

Senior High School	54

Tertiary	96

Post-Graduate	14

Uneducated	2

Total	244

Tribe

Akan	112

Ewe	58

Ga	44

Northern	30

Total	244

Parity

Zero	156

1 and above	88

Total	244

Body Mass Index

<25	76

25–29.9	78

30 and above	90

Total	244

Menstrual flow pattern (heavy flow)

Yes	102

No	142

Total	244

Type of menstrual cycle (irregular)

Yes	164

No	80

Total	244


Maturation - CD27/CD45RA	Differentiation - CD27/CD28


Included patients	Time ABI measurement1(min) Mean (SD)


Instruments	Domains	Mean ± Standard Deviation

JSS	Payment–promotion	3.38 ± 0.65

Management–interpersonal relationship	4.33 ± 0.66

Organization–communication	4.41 ± 0.70

Total score	3.92 ± 0.55

TAS-20	Difficulty describing feelings	12.97 ± 5.48

Difficulty identifying feelings	13.90 ± 5.18

Externally oriented thinking	18.01 ± 4.27

	Total score	44.89 ± 11.56

Instruments	Domains	Mean ± Standard Deviation

JSS	Payment–promotion	3.38 ± 0.65

Management–interpersonal relationship	4.33 ± 0.66

Organization–communication	4.41 ± 0.70

Total score	3.92 ± 0.55

TA	Difficulty describing feelings	12.97 ± 5.48

Difficulty identifying feeling	13.

Instruments	Domains	Mean ± Standard Deviation

S-20	s	90 ± 5.18

Externally oriented thinking	18.01 ± 4.27

	Total score	44.89 ± 11.56


Variable	Odds ratio	95 % confidence interval	p value

Moderate to high side effects (ref: no/low side effects)	4.84	1.07–1.85	0.04


	Six County Study Area	Entire State of Michigan

Current smoking	25.1%	25.1%

Heavy drinking (60+ drinks/mo)	2.6%	3.7%

Binge drinking (5+ drinks on 1+ occasions in past month)	7.6%	11.7%

Cholesterol never checked	16.1%	19.3%

Ever told cholesterol high (among tested)	37.4%	33.0%

Ever told high blood pressure	33.6%	31.4%

Overweight (BMI >= 27.8 for men, >= 27.3 for women)	34.6%	33.4%

Never had mammogram (among women 40+)	19.0%	22.2%

	 Study Area

Current smoking	25.1%	25.1%

Heavy drinking (60+ drinks/mo)	2.6%	3.7%

Binge drinking (5+ drinks on 1+ occasions in past month)	7.6%	11.7%

Cholesterol never checked	16.1%	19.3%

Ever told cholesterol high (among tested)	37.4%	33.0%

Ever told high blood pressure	33.6%	31.4%

Overweight (BMI >= 27.8 for men, >= 27.3 for women)	34.6%	33.4%

Never had mammogram (among women 40+)	19.0%	22.2%


Stratification criteria

Variable	Criteria

Student mobility

IHE-Yes	Any respondent declaring at least one study-related trans-border movement

IHE-No	Any respondent declaring no study-related trans-border movement

IHE-North	Destination countries of international health electives (IHE) are pre-dominantly industrialised countries.(Eligible combinations: n, nn, snn, nns, nsn, nnn)*

IHE-South	Destination countries of international health electives (IHE) are pre-dominantly developing countries.(Eligible combinations: s, ss, sn, ns, ssn, sns, nss, sss)*

Exposure to educational interventions

GH-yes	Any respondent declaring a participation in global health courses.

GH-no	Any respondent declaring no participation in global health courses.

TM-yes	Any respondent declaring a participation in courses of tropical medicine.

TM-no	Any respondent declaring no participation in courses of tropical medicine.

Stratification criteria

Variable

Student mobility

IHE-Yes

IHE-No

IHE-North

IHE-South

Exposure to educational interventions

GH-yes

GH-no

TM-yes

TM-no

Stratification criteria

Criteria

Any respondent declaring at least one study-related trans-border movement

Any respondent declaring no study-related trans-border movement

Destination countries of international health electives (IHE) are pre-dominantly industrialised countries.(Eligible combinations: n, nn, snn, nns, nsn, nnn)*

Destination countries of international health electives (IHE) are pre-dominantly developing countries.(Eligible combinations: s, ss, sn, ns, ssn, sns, nss, sss)*

Any respondent declaring a participation in global health courses.

Any respondent declaring no participation in global health courses.

Any respondent declaring a participation in courses of tropical medicine.

Any respondent declaring no participation in courses of tropical medicine.


	NP	Gestational day 20	Gestational day 50

Endometrium	Chorioallantoic membrane	Endometrium	Chorioallantoic membrane

H	A	H	A	H	A	H	A

PCR samples (No.)	5	30	19	26	20	29	6	27	4

WB samples (No.)	-	6	6	6	6	6	6	6	6

IF samples (No. of sections from different animals)	-	3	3	3	3	3	3	3	3

	NP	Gestational day 20

Endometrium	Chorioallantoic membrane

H	A	H

PCR samples (No.)	5	30	19	26

WB samples (No.)	-	6	6	6

IF samples (No. of sections from different animals)	-	3	3	3

Gestational day 20	Gestational day 50

Chorioallantoic membrane	Endometrium	Chorioallantoic membrane

A	H	A	H	A

20	29	6	27	4

6	6	6	6	6

3	3	3	3	3


Antigens	Patient (n)	Control (n)	Adjusted r2	pa

Combined	0.80±0.43 (200)	0.95±0.54 (220)	0.017	0.003


SOA	Compatibility group	Incompatibility group

	d'id	d'loc	d'id	d'loc

EXP. 1

	2.27*	0.12*	1.73*	−0.25*


Scenario	Parameter	Settings

A1–A5	Signal to noise (s2n)	0.01, 0.05, 0.1, 0.15, and 0.20

B1–B5	Mean of significant variables in the case	10, 15, 20, 25, and 30

C1–C5	Dispersion parameter of significant variables in the case	0.125, 0.5, 1, 2, and 8

 	Sample size (+/−)	40 (20/20)

 	Number of variables	500

 	Mean of significant variables in the control	5

 	Mean of insignificant variables	5

 	Dispersion parameter of significant variables in the control	1

 	Dispersion parameter of insignificant variables	1


Variables	p value	OR	95% CI for OR

Lower	Upper

Variables associated with diarrhea in children aged more than 6 months

Starting of breastfeeding

 After an hour of birth	0.045	1.479	1.009	2.166

 Within hour (reference category)

Nutritional status of children	0.029

 Moderate malnutrition	0.758	0.909	0.497	1.666

 Overweight	0.209	0.695	0.394	1.227

 Severe malnutrition	0.018	1.853	1.111	3.089

 Normal (reference category)

Duration of breastfeeding

 Up to 2 years	0.026	2.506	1.114	5.638

 2 years or more (reference category)

Variables associated with cough and cold in children aged more than 6 months

Hand washing before each feed

 Always (reference category)

 Sometimes	0.039	0.620	0.394	0.977

Nutritional status of child	0.115

 Moderate malnutrition	0.590	1.221	0.590	2.527

 Overweight	0.636	1.182	0.591	2.363

 Severe malnutrition	0.015	2.135	1.159	3.933

 Normal (reference category)

Washing utensils after each feed

 After each feed (reference category)

 Sometimes	0.001	0.457	0.282	0.740

Occupation

 Employed	0.022	0.546	0.325	0.916

 Housewife (reference category)


Culture medium/additives	Manufacturer	Order no.	Concentration

Dulbecco’s modified Eagle medium (DMEM) with l-glutamine, plus 4.5 g glucose, without NaHCO3, without Natriumpyruvate	Life Technology, Carlsbad, USA	11966-025

Penicillin/streptomycin	Life Technology, Carlsbad, USA	15640-055	100 IU penicillin/100 μg streptomycin/ml

Ca2+/Mg2+ free Hanks’ balanced salt solution (HBSS)–buffer	Life Technology, Carlsbad, USA	14170-070

Fetal calf serum (FCS)	Life Technology, Carlsbad, USA	10270-098	10%

l-Glutamate	Life Technology, Carlsbad, USA	25030-024	1%

Ethylenediaminetetraacetic acid (EDTA) solution	Sigma Aldrich, St. Louis, USA	E7889	0.5 M

l-Ascorbic acid 2-phosphate	Sigma Aldrich, St. Louis, USA	A-8960	1 mmol/l ASC (affinity isolated antibody)

Dexamethasone	Serva Bioproducts, Heidelberg, Germany	18660	100 nmol/l

Culture medium/additives	Manufacturer	Order no.	Concentration

Fetal calf serum (FCS)	Life Technology, Carlsbad, USA	10270-098	10%

l-Glutamate	Life Technology, Carlsbad, USA	25030-024	1%

Ethylenediaminetetraacetic acid (EDTA) solution	Sigma Aldrich, St. Louis, USA	E7889	0.5 M

l-Ascorbic acid 2-phosphate	Sigma Aldrich, St. Louis, USA	A-8960	1 mmol/l ASC (affinity isolated antibody)

Dexamethasone	Serva Bioproducts, Heidelberg, Germany	18660	100 nmol/l


Variable (units)	Low-salt sweat	Typical Sweat

<30 mmol·L−1 [sweat Na+]	30–60 mmol·L−1 [sweat Na+]

Number/Frequency	42/27 %	84/54 %

Men/women	37/5	73/11

Sweat Na+ concentration (mmol·l−1)	21.4 ± 6.4*	43.2 ± 8.8

Sweat Cl− concentration (mmol·l−1)	16.4 ± 4.3*	31.9 ± 9.9

Sweat K+ concentration (mmol·l−1)	5.9 ± 0.9	5.9 ± 0.9

Sweat osmolality (mOsm·kg H2O−1)	100.8 ± 38.9*	150.4 ± 42.1

Sweat rate (L·h−1)	0.9 ± 0.2	0.9 ± 0.3

Sweat NaCl loss (g L−1)	1.1 ± 0.3*	2.1 ± 0.5

Fluid intake (L·h−1)	0.32 ± 0.18	0.31 ± 0.17

Na+ intake (mmol)	12.3 ± 8.1	11.9 ± 9.9

Cl− intake (mmol)	21.3 ± 13.0	20.8 ± 15.0

K+ intake (mmol)	5.1 ± 6.0	4.7 ± 7.9

Running pace (m·s−1)	3.0 ± 0.4	3.1 ± 0.5

Average training distance·week−1 (km)	65.1 ± 32.0	60.5 ± 26.7


Fold enrichment (P value)	↑ in Dupl5q cortex	↓ in Dupl5q cortex	↑ In idiopathic ASD cortex	↓ In idiopathic ASD cortex

All genes	↑ 1500 in DPSC neurons	1.41(le-6)	1.06(0.5)	1.25(0.05)	1.14(0.3)

↓ 1500 in DPSC neurons	0.87(0.1)	0.95(0.6)	0.97(0.8)	1.07(0–6)

All genes except 15qll-13 genes	↑ 1500 in DPSC neurons	1.37(le-5)	1.07(0.4)	1.26(0.04)	1.09(0.5)

↓ 1500 in DPSC neurons	0.88(0.1)	0.95(0.6)	0.96(0.8)	1.08(0.5)

Fold enrichment (P value)	↑ in Dupl5q cortex	↓ in Dupl5q cortex	↑ In idiopathic ASD cortex	↓ In idiopathic ASD cortex

All genes	↓ 1500 in DPSC neurons	0.87(0.1)	0.95(0.6)	0.97(0.8)	1.07(0–6)

All genes except 15qll-13 genes	↑ 1500 in DPSC neurons	1.37(le-5)	1.07(0.4)	1.26(0.04)	1.09(0.5)

↓ 1500 in DPSC neurons	0.88(0.1)	0.95(0.6)	0.96(0.8)	1.08(0.5)


Cytological findings	Final histological diagnosis

SQC	SCLC	ADC	ADC/SQC	LC/LNC	Carcinoid	Other	Benign	Total

SQC	47	0	9	1	6	0	0	0	63

SCLC	0	3	1	0	3	0	0	0	7

ADC	1	0	107	1	3	0	0	0	112

LC/LNC	0	0	1	0	1	0	0	0	2

Carcinoid	0	0	3	0	1	13	0	0	17

Other	0	0	0	0	1	0	0	0	1

Susp.	0	0	1	0	0	0	0	0	1

Benign	6	0	14	1	5	2	0	84	112

Total	54	3	136	3	20	15	0	84	315


	Males

Age (years)	55 ± 10

Stature (cm)	177.6 ± 5.5

Body mass (kg)	85.92 ± 12.50

BMI	27.54 ± 4.11


Parameter	n* (%)

Gender 	86

 Male	42 (48.8)

 Female	44 (51.2)

Age	86

 Range, 13.5–85.4 years	—

 Mean, 55.0 years	—

 Median, 57.2 years	—

Tumor size	78

 Range, 2.0–8.5 cm	—

 Mean, 4.9 cm	—

 Median, 5.0 cm	—

Tumor location	86

 Parasagittal-falcine	26 (30.2)

 Convexity	35 (40.7)

 Base	24 (27.9)

 Frontal/frontobasal	16 (18.6)

Tumor site	86

 Left	37

 Right	31

 Bilateral	18

Duration of signs/symptoms	80

 Range, 0–36 months	—

 Mean, 7.5 months	—

 Median, 4.0 months	—

Presenting signs/symptoms	83

 Headache	23 (25.9)

 Hemiparesis	22 (36.6)

 Seizures	20 (24.7)

 Behavior changes	12 (14)

 Cranial nerve palsy 	6 (11.1)

Behavior changes	83

 Present	30 (36.1)

 Absent	53 (73.9)

Edema	58

 Absent	10 (17.2)

 Mild 	31 (53.4)

 Severe	17 (29.3)

Cleavability	42

 Cleavable 	18 (42.9)

 Noncleavable	24 (57.1)

Parameter	n* (%)

Tumor size	78

Range, 2.0–8.5 cm	—

Mean, 4.9 cm	—

Median, 5.0 cm	—

Tumor location	86

Parasagittal-falcine	26 (30.2)

Convexity	35 (40.7)

Base	24 (27.9)

Frontal/frontobasal	16 (18.6)

Tumor site	86

Left	37

Right	31

Bilateral	18

Duration of signs/symptoms	80

Range, 0–36 months	—

Mean, 7.5 months	—

Median, 4.0 months	—

Presenting signs/symptoms	83

Headache	23 (25.9)

Hemiparesis	22 (36.6)

Seizures	20 (24.7)

Behavior changes	12 (14)

Cranial nerve palsy	6 (11.1)

Behavior changes	83

Present	30 (36.1)

Absent	53 (73.9)

Edema	58

Absent	10 (17.2)

Mild	31 (53.4)

Severe	17 (29.3)

Cleavability	42

Cleavable	18 (42.9)

Noncleavable	24 (57.1)


SNP	Chr	Position	Related gene	Minor allele	MAF in telomere GWAS [13]	MAF in our data	Average imputation R-square1	Melanoma beta2	Melanoma P value2	Nevus count beta	Nevus count P value

rs1		169492101	TE	T	0.252	0.241	0.993	−0.	0.		0.4


Antibody	Staining pattern	Clone	Antigen retrieval	Dilution	Source	Interobserver variability (kappa)

ER	Nuclear	SP1	EDTA pH 9	1:80	Immunologic	0.959

PR	Nuclear	PgR636	EDTA pH 9	1:500	Dako	0.961

MLH1	Nuclear	G168-15	EDTA pH 9	1:40	BD	0.894

PMS2	Nuclear	A16-4	EDTA pH 9	1:100	BD	0.800

MSH2	Nuclear	GB12	EDTA pH 9	1:20	Calbiochem	0.848

MSH6	Nuclear	EPR3945	EDTA pH 9	1:1000	Abcam	0.763

PTEN	Nuclear and cytoplasmic	6H2.1	EDTA pH 9	1:100	Dako	0.724

IMP3	Cytoplasmic	69.1	EDTA pH 9	1:50	Dako	0.912

β-Catenin	Membranous and cytoplasmic	14/β-catenin	EDTA pH 9	1:200	BD	0.911

L1CAM	Membranous	14.10	EDTA pH 9	1:100	BioLegend	0.921

Ki-67	Nuclear	MIB-1	Citrate pH 6.0	1:40	Dako	0.998

ARID1A	Nuclear	HPA005456	Citrate pH 6.0	1:100	Sigma	0.796

Stathmin	Cytoplasmic	3351	Citrate pH 6.0	1:50	Cell Signaling	0.824

P53	Nuclear	DO-7	Citrate pH 6.7	1:200	Immunologic	0.901

P16	Nuclear and cytoplasmic	MX007	HIER pH 8.0	1:60	Immunologic	0.779

Antibody	Staining pattern	Clone	Antigen retrieval	Dilution	Source	Interobserver variability (kappa)

ER	Nuclear	SP1	EDTA pH 9	1:80	Immunologic	0.959

PR	Nuclear	PgR636	EDTA pH 9	1:500	Dako	0.961

MLH1	Nuclear	G168-15	EDTA pH 9	1:40	BD	0.894

PMS2	Nuclear	A16-4	EDTA pH 9	1:100	BD	0.800

MSH2	Nuclear	GB12	EDTA pH 9	1:20	Calbiochem	0.848

MSH6	Nuclear	EPR3945	EDTA pH 9	1:1000	Abcam	0.763

PTEN	Nuclear and cytoplasmic	6H2.1	EDTA pH 9	1:100	Dako	0.724

IMP3	Cytoplasmic	69.1	EDTA pH 9	1:50	Dako	0.912

β-Catenin	Membranous and cytoplasmic	14/β-catenin	EDTA pH 9	1:200	BD	0.911

L1CAM	Membranous	14.10	EDTA pH 9	1:100	BioLegend	0.921

Ki-6	Nucle		Ci	1:40	D	0

7	ar	MIB-1	trate pH 6.0		ako	.998

ARID1A	Nuclear	HPA005456	Citrate pH 6.0	1:100	Sigma	0.796

Stathmin	Cytoplasmic	3351	Citrate pH 6.0	1:50	Cell Signaling	0.824

P53	Nuclear	DO-7	Citrate pH 6.7	1:200	Immunologic	0.901

P16	Nuclear and cytoplasmic	MX007	HIER pH 8.0	1:60	Immunologic	0.779


Source	Average degree	Average distance	Clustering coefficient	Diameter

Figure 4 (NESG IDs)	19	2.7	0.43	6

Figure 4 (JCSG IDs)	45	1.5	0.46	3

Figure 4 (TB IDs)	6.7	2.0	0.46	4

Figure 5a (DNA pol IDs)	15	3.1	0.44	7

Figure 5b (RNA pol IDs)	13	3.1	0.44	7

Figure 6a (PSI IDs)	24	2.6	0.37	7

Figure 6b (PDB IDs 1)	6.1	3.9	0.31	9

Figure 6b (PDB IDs 2)	6.7	3.8	0.33	10

Source	Average degree	Average distance	Clustering coefficient	Diameter

Figure 6b (PDB IDs 1)	6.1	3.9	0.31	9

Figure 6b (PDB IDs 2)	6.7	3.8	0.33	10


	Path coefficient

	To BMI

	b	SE	β

Leptin	0.82	0.27	0.72**

Total	21.96	9.58	0.48*


		Meters above sea level (masl)c		Mean annual temperature(matp)d	Mean annualrainfall (mar)e	Buffaloes tested	Seropositivity toT. gondii

Regiona	Municipalityb	Climate	No.	No.	%

Olmeca	Las Choapas	10	Warm	27.0°C	2900 mm	58	21	36.2

	Sayula de Alemán	80	Warm	27.0°C	1650 mm	156	93	59.6

	All					214	114	53.3

Papaloapan	Isla	60	Warm-humid	24.9°C	2316 mm	59	23	39.0

	J. Rodriguez Clara	95	Warm	25.0°C	1266 mm	66	28	42.4

	All					125	51	40.8

All						339	165	48.7


Cell line

In vitro	Single BR (μg/ml)	Single NAC (mM)	Combination (BR + NAC)

MKN45	3, 6	300, 500	3 + 300, 3 + 500, 6 + 300, 6 + 500


	Young-old	Old-old

Incidence rate	95% CI	Incidence rate	95% CI

≥ 85	–	–	83.3	71.8–96.8

Educational attainment

< 10 yrs	10.2	9.2–11.3	42.6	39.4–45.9

≥ 10 yrs	8.9	7.8–10.1	36.2	32.6–40.1


	Total (n = 355)	Odds ratio (95% confidential interval)	P-Value

emale		.09 (0.45, 2.66)	5

Education

Higher secondary	164	1.00

Degree-PG	191	0.846 (0.34, 2.12)	0.721

Geographic location

Rural	249	1.00

Urban	106	1.399 (0.68, 2.87)	0.36

Stakeholders

Students	124	1.00

Teachers	105	0.577 (0.11, 3.07)	0.519

Persons engaged in social service	76	0.160 (0.05, 0.53)	0.003

Kin of the family members	50	1.301 (0.26, 6.48)	0.748


Experiment a	Coded Values b	Planned Values c

t	V	H	Agitation Time (min)	ACN (mL)	Homogenization Time (s)

1	1	0				10.


	Nondiabetics	Diabetics	Univariate (P)

Median age (Years)	48.0	52.5	0.207

T


	Sensitivity

	P(CH = 1|SR = 1)

Full sample	0.90

Age

25-34	0.71

35-49	0.86

50+	0.95

Gender

Females	0.88

Males	0.9

Marital Status

Currently Married	0.90

Not Married	0.89

Race/ethnicity

Latino	0.89

non-Hispanic White	0.90

non-Hispanic Black	0.90

Education

<12	0.92

12	0.79

12+	0.86

Annual Household Income

<$10,000	0.77

$10,000-19,999	0.92

$20,000-34,999	0.89

$35,000+	0.97


In silico SNP performance assessment	F0	F1	F2	F3	F4

# of SNPs	66,254	21,944	10,032	3,187	1,329

# of contigs with SNPs	9,579	5,058	2,057	1,651	998

# of SNPs submitted to the ADT	621	605	583	367	547

# of SNPs with ADT Score ≥ 0.6	598	572	557	353	525

% of SNPs with ADT Score ≥ 0.6	96.3	94.5	95.5	96.2	96.0

# of SNPs with ADT Score ≥ 0.9	314	316	297	177	291

% of SNPs with ADT Score ≥ 0.9	50.6	52.2	50.9	48.2	53.2

# of SNPs tested by the GGGT	96	96	108	108	288

In silico SNP performance assessment	F0	F1	F2	F3	F4

# of SNPs	66,254	21,944	10,032	3,187	1,329

# of contigs with SNPs	9,579	5,058	2,057	1,651	998

# of SNPs submit		605	58	367	547

ted to the ADT	621		3

# of SNPs with ADT Score ≥ 0.6	598	572	557	353	525

% of SNPs with ADT Score ≥ 0.6	96.3	94.5	95.5	96.2	96.0

# of SNPs with ADT Score ≥ 0.9	314	316	297	177	291

% of SNPs with ADT Score ≥ 0.9	50.6	52.2	50.9	48.2	53.2

# of SNPs tested by the GGGT	96	96	108	108	288


Name	2010	2013	Difference

	h-core 	h-	B	h-core cit	h	Bh-I	h-core citations	h-I


abbreviation	muscle name	maximum isometric force (Fiso, N)	optimal fibre length (Lfopt, m)	tendon slack length (Ltsl, m)	pennation angle (°)

IC	M. iliotibialis cranialis	889	0.174	0.0451	0

ILa	M. iliotibialis lateralis (cranial part)	1265	0.174	0.2432	0

ILp	M. iliotibialis lateralis (caudal part)	1265	0.174	0.3099	0

AMB1	M. ambiens, ventral (pubic) head	971	0.039	0.1648	10

AMB2	M. ambiens, dorsal (iliac) head	1793	0.044	0.3941	15

FMTL	M. femorotibialis lateralis	1434	0.088	0.1746	15

FMTIM	M. femorotibialis intermedius	1706	0.084	0.1863	25

FMTM	M. femorotibialis medialis	1089	0.089	0.0603	30

ILFBa	M. iliofibularis (cranial part)	1254	0.176	0.2134	0

ILFBp	M. iliofibularis (caudal part)	1254	0.176	0.2733	0

ITCa	M. iliotrochantericus caudalis (cranial part)	897	0.064	0.0469	25

ITCp	M. iliotrochantericus caudalis (caudal part)	897	0.064	0.038	25

IFE	M. iliofemoralis externus	479	0.025	0.0667	25

ITM	M. iliotrochantericus medius	181	0.058	0.0241	0

ITCR	M. iliotrochantericus cranialis	330	0.053	0.0488	10

IFI	M. iliofemoralis internus	410	0.041	0.0533	0

FCM	M. flexor cruris medialis	1109	0.036	0.435	35

FCLP	M. flexor cruris lateralis pars pelvica	544	0.24	0.2449	0

ISF	M. ischiofemoralis	419	0.033	0.0816	15

PIFML	M. puboischiofemorales medialis + lateralis	816	0.089	0.1669	15

OM	M. obturatorius medialis	3124	0.055	0.1651	25

CFP	M. caudofemoralis pars pelvica (et caudalis)	1125	0.108	0.215	15

GL	M. gastrocnemius pars lateralis	1836	0.12	0.5818	20

GIM	M. gastrocnemius pars intermedius	798	0.125	0.507	15

GM	M. gastrocnemius pars medialis	3124	0.094	0.5957	20

FL	M. fibularis longus	2270	0.081	0.9633	20

FDL	M. flexor digitorum longus	1130	0.048	1.0366	20

FPPD3	M. flexor perforans et perforatus digitorum 3	1154	0.025	1.0737	30

FPD3	M. flexor perforans digitorum 3	3210	0.017	1.02	35

FPD4	M. flexor perforans digitorum 4	1434	0.026	1.004	20

FHL	M. flexor hallucis longus	469	0.04	1.0939	25

EDL	M. extensor digitorum longus	833	0.049	0.8512	30

TCf	M. tibialis cranialis (femoral head)	686	0.045	0.4791	25

TCt	M. tibialis cranialis (tibial head)	686	0.045	0.4215	25


Predictors (all T1 variables)	Odds Ratio	95% CI

Independent

Neighborhood crime	0.91	0.75–1.10

Neighborhood drug selling/use	1.39	1.16–1.66

Noxious neighborhood	1.03	0.90–1.19

Controls

Age	1.51	1.22–1.85

Sex (Ref = Male)	0.64	0.43–0.95

SES	1.08	0.88–1.30

Occasions of marijuana use	1.78	1.31–2.42

Predictors (all T1 variables)

Independent

Neighborhood crime

Neighborhood drug selling/use

Noxious neighborhood

Controls

Age

Sex (Ref = Male)

SES

Occasions of marijuana use


	Sense primer (5′ to 3′)	Anti-sense primer (5′ to 3′)

Human CCL19	CCAACTCTGAGTGGCACCAA	TGAACACTACAGCAGGCACC

Human CCL21	TGGCCTCTTACTCACCCTCT	GCCTCTTGATCCCCTTAGCC

Human CCR7	GCCTACGACGTCACCTACAG	GGCAGAAGAGTCGCCTATGG

Beta-actin	CCATCGTCCACCGCAAAT	TGTCACCTTCACCGTTCC

ALP	ATCTTTGGTCTGGCTCCCATG	TTTCCCGTTCACCGTCCAC

Human OCN	GGCAGCGAGGTAGTGAAGAG	CTGGAGAGGAGCAGAACTGG

Human COL1	GAG AGC ATG ACC GAT GG	GTG ACG CTG TAG GTG AA

IBSP	CGCCAATGAATACGACAATG	GATGCAAAGCCAGAATGGAT

Human VEGF-A	GAGCCTTGCCTTGCTGCTCTA	CACCAGGGTCTCGATTGGAT

Runx-2	GCAGCAACCCAGAAACACTT	AACACATGACCCAGTGCAAA

Osterix	AGAGGAGAGACTCGGGACAG	GAGTTGTTGAGTCCCGCAGA

	Sense primer (5′ to 3′)	Anti-sense primer (5′ to 3′)

Osterix	AGAGGAGAGACTCGGGACAG	GAGTTGTTGAGTCCCGCAGA


	ASD (n = 9)	Neurotypical (n = 9)

	Mean	SD	Mean	SD

Chronological age (years)	13.67	1.94	14.44	1.13

WASI vocabulary	52	10.99	63.78	6.72

WASI matrix	49.78	7.12	55.44	8.75

WASI IQ	101.78	13.84	117.22	13.15

ADOS

Communication	3.11	0.93	0.22	0.44

Social interaction	5.44	2.19	0.11	0.33

Communication and social interaction total	8.56	2.92	0.33	0.5

Stereotyped behaviors and restricted interests	2.0	1.41	0	0


Characteristics	ORT corner users, n(%)	ORT corner non-users, n(%)	p value

Age:			0.4905

 18-19 years	9(8)	11(9)

 20-29 years	48(44)	63(53)

 30-39 years	33(39)	35(30)

 40 and over	10(9)	9(8)

Education:			0.1048

 No formal education	59(54)	61(52)

 Primary or secondary education	33(30)	34(29)

 Tertiary education	10(9)	4(3)

 Other	8(7)	18(15)

Occupation:			0.0016*

 Housewives	35(32)	58(48)

 Petty traders	58(53)	55(46)

 Government employee	15(13)	2(2)

 Students	0(0)	2(2)

 Other	2(2)	2(2)

Religion: Muslim	106(96)	112(94)	0.4271

Marital Status: Married	101(92)	113(95)	0.3373

Number of children, Mean	4.2	3.3	0.0027*

Characteristics	ORT corner users, n(%)	ORT corner non-users, n(%)	p value

Age:			0.4905

18-19 years	9(8)	11(9)

20-29 years	48(44)	63(53)

30-39 years	33(39)	35(30)

40 and over	10(9)	9(8)

Education:			0.1048

No formal education	59(54)	61(52)

Primary or secondary education	33(30)	34(29)

Tertiary education	10(9)	4(3)

Other	8(7)	18(15)

Occupation:			0.0016*

Housewives	35(32)	58(48)

Petty traders	58(53)	55(46)

Government 	15(1	2(

Characteristics	ORT corner users, n(%)	ORT corner non-users, n(%)	p value

employee	3)	2)

Students	0(0)	2(2)

Other	2(2)	2(2)

Religion: Muslim	106(96)	112(94)	0.4271

Marital Status: Married	101(92)	113(95)	0.3373

Number of children, Mean	4.2	3.3	0.0027*


	N = 137 patients (23 residents)

Physician's Use of Obesity Counseling

 % Counseled about Obesity (n)	85.4 (117)

 Mean Number of Counseling Practices1 (SD) (18 Items total)	5.3 (4.6)

5As

 Mean Number of Assess2 Practices (SD) (6 items)	2.2 (2.0)

 Mean Number of Advise3 Practices (SD) (4 items)	1.3 (1.3)

 Mean Number of Agree4 Practices (SD) (3 items)	0.7 (1.2)

 % Use Assist5 Practice (n) (1 item)	25.6 (35)

 Mean Number of Arrange6 Practices (SD) (4 items)	0.8 (0.4)


Characteristics	No. of patients (%)

Age (years)

 Median (range)	71.0 (65.0-81.0)

ECOG performance status

 0-1	108 (81.2)

 ≥ 2	25 (18.8)

BMI (kg/m2)

 < 30	96 (72.2)

 ≥ 30	37 (27.8)

WIC

 ≥ 1	52 (39.1)

 < 1	81 (60.9)

Baseline LVEF

 Median (range)	61% (47.0–69.0)

TNM stage

 I-II	39 (29.3)

 III	61 (45.9)

 IV	33 (24.8)

Anthracycline exposure

 Previous	49 (36.8)

 Concomitant	22 (16.5)

 None	62 (46.6)

Anthracycline cumulative dose (mg/m2)	116 (0-540)

Previous radiotherapy (thoracic wall)

 Yes	19 (14.3)

 No	124 (93.2)

Characteristics

Age (years)

Median (range)

ECOG performance status

0-1

≥ 2

BMI (kg/m2)

< 30

≥ 30

WIC

≥ 1

< 1

Baseline LVEF

Median (range)

TNM stage

I-II

III

IV

Anthracycline exposure

Previous

Concomitant

None

Anthracycline cumulative dose (mg/m2)

Previous radiotherapy (thoracic wall)

Yes

No


Number of Procedures	< 200h	> 200h	p value

History Takings in Initial Patient Care	136.905	363.800	0.001075

Non-cast immobilizations	19.360	63.577	0.005303793

Cast immobilizations	32.811	102.160	0.000295235

Simple sutures	33.980	96.200	0.000032826369841

Donatti sutures	5.283	12.214	0.019836

Trauma Resuscitation Room visits	2.804	21.036	0.000045965


	Adolescent population*	Adolescents with emergency admission(s) for injury between 10 and 19 years of age, n (row %)

Characteristics	Total	Total	Adversity	Accidents only	Other causes

All	3 254 046	402 916 (100.0)	141 248 (35.1)	233 907 (58.1)	27 761 (6.9)

Age†


Month	Cross-validation (%)	Allometry (%)	Influential landmark

♂	♀

JAN/2009	Hilltop	81	93	10.470*	#10 and #17

Lowland	100	100	15.968*	#2 and #9

JAN/2012	Hilltop	87	96	5.853*	#2 and #9

Lowland	76	77	2.141	#10 and #17